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A sower went out to sow his seed; and as he sowed, 
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and the birds of the air devoured it. And some fell on 
the rock; and as it grew up, it withered away, because it 
had no moisture. And some fell among thorns; and the 
thorns grew with it and choked it. And some of it fell 
into good soil and grew... 
-Luke 8: 4-8, R.S.V. 
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AN EFFECTIVE NEW 
PROGNOSTIC STAGING SYSTEM FOR 
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 
Amy Caroline Justice 
1988 
To evaluate promising new treatments for acquired 
immunodeficiency syndrome (AIDS), without the ethical dilemma of 
concurrent placebo' controls, an effective system is needed for 
prognostic staging. Such a system has not been developed, because 
investigators have either concentrated on the prognostic transition 
from HIV-positivity to overt AIDS, or have staged the overt syndrome 
mainly according to morphologic evidence. In 76 consecutive patients 
with AIDS treated at Yale-New Haven Hospital during 1981-86, 3 
major functional deficits were found to be important predictors of 
death. They were: substantial neurologic deficit (e.g. seizures, severe 
lethargy, aphasia); severe hypoxemia (arterial pOo < :>0); or any 1 of 3 
cytopemas (Hematocrit <35, WBC <2,500, or ^platelets <140,000). 
Stage III was assigned to patients with "bone marrow" failure, classified 
as any 2 of the 3 cytopenias; Stage II was assigned for any of the 
neural, respiratory, or single hematologic deficits; and Stage I had 
none of the deficits. For the "development set" of 76 patients, 4-month 
survival rates in the three stages were I, 25/28 (89%); II, 19/38 (50%): 
and IIF 3/10 (30%). The corresponding median months of survival 
were 10.8, 3.85, and 2.3. The next 42 consecutive patients during 1986- 
87 were used as a "challenge set". The corresponding survival rates for 
16, 19, and 7 persons in each stage were I, 69%; II, 42%; and III, 29% 
at 4 months, with median survival times of 7.2, 1.6, and 0.7 months. 
The challenge set results thus confirmed the prognostic gradient. 
This prognostic staging system, basea on functional deficits, is 
simple to use, noninvasive, and inexpensive. It offers an effective way 
to predict prognosis for individual patients, and to improve evaluations 





This thesis concerns the development and testing of a prognostic 
classification system for Acquired Immunodeficiency Syndrome 
(AIDS). The system, which is founded on functional criteria, will be 
useful in predicting individual patient prognosis and in evaluating 
therapeutic trials. 
The introductory discussion contains two parts. The first part gives 
a brief historical account of the characterization of AIDS, its causal 
agent and current predictions of the ensuing epidemic. The second 
part considers the potential applications of a prognostic stratification 
and offers a critical review of currently proposed classification systems 
and prognostic variables. 
Historical Background 
Initial Description and Recognition of Risk Groups: 
Less than seven years ago AIDS was completely unknown. In the 
summer of 1981 the Center for Disease Control (CDC) reported five 
cases of Pneumocystis carinii and 26 cases of Kaposi’s sarcoma in 
young, previously healthy, homosexual men.l-^ The CDC recognized 
the importance of clearly defining this syndrome to allow consistent 
reporting. By 1983, the CDC had published guidelines for a clinical 
definition based on the presence of reliably diagnosed disease at least 
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moderately predictive of an underlying cellular immunodeficiency.^ 
At this time the CDC excluded known causes of underlying 
immunodeficiency or host defense defect, such as immunosuppressive 
therapy or lymphoreticular malignancy. The CDC criteria, recognizing 
that the causative agent seemed to be transmitted in blood and blood 
products, defined certain high risk groups that included homosexual 
men, intravenous drug abusers (IVDA’s), persons who had received 
large transfusions of blood or blood products, and sexual partners of 
anyone known to be at high risk. (Haitians were originally included as 
a separate risk group but were later excluded.)^“4 A distinct 
syndrome, AIDS-related complex (ARC), was subsequently recognized 
and described as a symptom complex that frequently preceded AIDS 
but did not always progress to the full-blown syndrome.^ 
Identification of the Virus: 
In the spring of 1984 Robert Gallo and Luc Montagnier, working in 
separate laboratories, identified what was eventually named the 
Human Immunodeficiency Virus (HIV) as the causative agent of 
AIDS.6'8 HIV is a human retrovirus that selectively infects and 
destroys T helper (T4) lymphocytes. Recent work has shown that the 
membrane glycoprotein CD4 is the cellular receptor for HIV. This 
receptor is found on T4 lymphocytes, macrophages, natural killer cells, 
some B lymphocytes and neuronal cells.^"^ 
Once the virus was identified, both laboratories quickly developed 
assays for human antibodies to major core proteins of the virus. These 
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assays allowed reliable identification of infected individuals even when 
• 11 1 ^ 
asymptomatic.11 
The CDC soon integrated antibody screening into the case 
definition,1^ as shown in Appendix la. Once an asymptomatic state of 
"HIV positivity" has been identified, an immediate emphasis was 
placed on describing prognostic indicators for the transitions from HIV 
positivity to ARC, and from ARC to AIDS. Relatively little attention 
was given to prognostic indicators for the outcome of overt AIDS. 
Epidemiologic Predictions: 
AIDS has rightfully been called a modern day plague. Conservative 
predictions are that 270,000 people in the United States will have 
AIDS by 1991 or will have already died from the disease.^ 
The potential human and economic costs are staggering. In New 
York City AIDS is already the leading cause of death among men and 
women ages 25-34 years; and 87% of people diagnosed with AIDS 
before 1983 are dead. 16 The New York City Department of Health 
currently estimates that by 1991 between 25-50% of New York City 
medical-surgical beds will be constantly occupied by AIDS and ARC 
patients.16 
As of now, AIDS has no curative therapy and no prophylactic 
vaccine. Although "safe sex" campaigns seem to have slowed the rate 
of rise in the homosexual community, warnings to use clean needles or 
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abstain from intravenous drug abuse have generally gone unheeded 
among the IVDA population.^ Drug abusers, a particularly difficult 
group to reach with new health measures, have become the most 
frequent victims of AIDS in New York City, and other cities will 
undoubtedly follow this trend. 
Historical Conclusions: 
This brief historical review shows that AIDS research has made 
remarkable progress in seven short years, but serious therapeutic needs 
remain. Although some treatments are available for particular 
opportunistic infections, none eradicate the virus itself. One drug, 
azidothymidine (AZT, now also called zidovurine^) has been made 
available for treating HIV infection,18-19 ^ut at 5est jt js palliative, not 
curative. 18-20 xhe need for a reliable prognostic stratification system 




Purpose of Prognostic Classification in AIDS 
Problems in the AZT Trial: 
In July 1987 Fischl et al. published a double-blind randomized 
placebo controlled trial of AZT.~0 Although originally designed to 
follow subjects for 24 weeks of therapy, the study was prematurely 
ended, with only 10% of its subjects having been followed for 24 weeks, 
when a special screening panel found a significant difference in 
mortality between the control and experimental groups. The mortality 
rates were 9/137 (6.6%) in the control group and 1/145 (0.7%) in the 
experimental group (P< 0.001). Because of the difference in mortality, 
the panel^ believed that continuation of the trial would be unethical. 
AZT was then made generally available to all AIDS and ARC 
patients at a yearly cost^ per patient of about $11,000.00. In a 
companion article Richman et al.^“ warned that AZT had serious 
toxicity among the patients in their study. Severe anemia, with 
hemoglobin levels < 7.5 grams per deciliter^, was found in 24% of 
AZT recipients but in only 4% of controls. Furthermore, the patients 
who were initially sicker, i.e. with already suppressed hematologic 
counts, were more likely to experience serious toxicity from AZT.^2 
Because the eligibility criteria for the clinical trial demanded that the 
AIDS patients be both within 120 days of their first bout of 
Pneumocystis carinii and free of any other opportunistic infection or 
neoplasm, the treated group contained only relatively healthy AIDS 
patients. The potentially high morbidity and mortality associated with 
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AZT in more severely ill AIDS patients has subsequently been 
demonstrated.^ 
Purposes of Prognostic Stratification in Therapeutic Trials: 
The AZT trial illustrates several roles for a reliable prognostic 
staging system: it can help prevent bias that may arise by chance in 
randomized trials; it can improve the identification of the historical 
control group when randomized placebo controlled trials are not 
possible or ethically permissible; and it can improve both therapeutic 
decisions for individual patients and therapeutic research for 
appropriate patient populations. These roles are discussed in the 
sections that follow. 
Randomized Controlled Trials: False Positives 
Double-blind, randomized placebo controlled trials are the "gold 
standard" of clinical research, but are not free from bias. The "luck of 
the draw" during randomization can produce prognostic disproportions 
in the groups being compared, and can thus create false positive 
results.^ Feinstein and Landis,^ using computer simulations for two 
ineffective therapies, showed that without prognostic stratification, a 
major statistical discrepancy can occur in about 25% of randomized 
trials with sample sizes of 100. These discrepancies were more likely to 
occur when patients in the different prognostic stages had sharp 
differences in the survival rates.^ 
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In the AZT trial, Fischl et al.20 made careful efforts to distribute 
AIDS and ARC patients evenly; and to compare the groups for age, 
body weight, Karnofsky performance score, number of symptoms, and 
mean T4 cells at entry. Nevertheless, certain major prognostic 
indicators may not have been included. For example, a particular 
symptom such as severe anemia might lead to a nadir survival rate of 
0% at four months. If such prognostic factors are ignored, and if the 
treated groups are not evenly distributed for the factors, the results 
might seem to show significantly different post-therapeutic effects even 
if the treatment itself was ineffective.^ These differences could be 
particularly emphasized by a short period of follow up, before 
sufficient time had elapsed for a real therapeutic effect. 
Flistoric Controls in the Absence of Randomized Controls 
Although randomized controlled trials can be significantly 
improved, an even more persuasive need for good prognostic 
stratification occurs when placebo controlled trials are regarded as 
unethical. Since this problem arose in the AZT trial, any further 
research with AZT will require historic controls rather than concurrent 
placebo controls. In the absence of concurrent placebo controls, 
prognostic staging can allow the compared historic controls to be 
adjusted for the severity of illness of the treated new group. In light of 
the pressing need for more comprehensive therapeutic research in 
AZT18,22-23 ancj the ethical difficulties of sham therapies in fatal 
diseases such as AIDS, reliable prognostic stratification could help 




Different Therapeutic Effects Among Strata: False Negatives 
False negative results may occur when prognostic strata are 
similarly distributed in compared cohorts but are affected differently 
by the compared treatments.^ The trial of AZT showed that its toxic 
effects were highest in the sickest patients. Because the trial included 
patients who were relatively healthy, it is possible that the apparently 
favorable response of early AIDS/ARC patients might be reversed in 
more severely ill patients. If future AZT testing does not include 
prognostic stratification, a false negative result might be produced as 
the bad outcomes in the sicker patients obscure a beneficial effect in 
the relatively healthy patients. For example, consider two prognostic 
strata being tested with two treatments, AZT and an ineffectual other 
drug. Suppose that AZT has a beneficial effect in healthy AIDS 
patients and a detrimental effect in sick cases. We might find the 














If the groups were not prognostically separated, the similar 50% 
survival rates in the total results would make the researchers falsely 
conclude that AZT was no more effective than the ineffectual agent 
A suitable prognostic separation would prevent this problem and 

would yield a valuable insight into the type of patient who could 
greatly benefit from AZT. 
Another aspect of better prognostication is its personal benefit to 
the patient. The results can help in plannig for the future, in choosing 
more appropriate therapies, and also in difficult decisions about when 
to stop heroic treatment.^ 
Current Classification Systems 
Two principles of prognostication should be recognized before 
beginning a review of current prognostic research on HIV. 
Basic Principles: 
The first important prognostic principle is that AIDS is a complex 
syndrome. It affects multiple organ systems and has multiple 
infectious and oncologic processes.^ This complexity cannot be 
effectively studied in isolated subsets that consider only patients with 
one particular manifestation of AIDS.^ Many papers have been 
written on isolated aspects of HIV infection (e.g. individual forms of 
opportunistic infections, various cancers, manifestations in different 
individual organ systems). These isolated accounts, however, do not 




A second principle of prognosis is that the prediction must be 
aimed at a specific phenomenon or target event.^4 In the case of HIV 
infection, prognostic research has emphasized two transitions: the 
change from membership in a high risk group to HIV infection; and 
the change from HIV infection to overt AIDS. Relatively little 
research attention has been given to the outcome of AIDS itself: the 
transition from AIDS to survival or death. It is the latter target event- 
survival with overt AIDS-with which this review is concerned. 
In general, a single prognostic variable or prognostic system cannot 
reasonably be expected to predict several different target events.24 
The prediction of the transition from risk group membership to HIV 
positivity is therefore beyond the scope of this review. The factors that 
predict initial infection are unlikely to differentiate survival among 
those already infected. Most persons who develop frank ARC or 
AIDS will probably have already demonstrated lymphadenopathy, 
fevers, or other factors that predict the progression. In addition, the 
virus itself cannot be held responsible for co-morbid factors (such as 
previous hepatitis B infection) or demographic factors (such as 
residence in New York city) that increase the predisposition to an 
initial infection. 
On the other hand, the features that predict progression from HIV 
infection to AIDS may offer important hints about the pathologic 
effects of the virus’s activity. If these predictive factors reflect or 
correlate with an actual pathologic process of immunologic decline, 
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they may also affect the patient’s ultimate survival after AIDS becomes 
clinically overt. 
This review is therefore concerned with two groups of studies. The 
first group consists of classification systems and clusters of variables 
designed to differentiate HIV infection and predict its transition to 
AIDS. The second group consists of the few studies that have 
considered survival in AIDS. 
CPC Definition of AIDS/ARC: 
The most influential current classification system for HIV infection 
has been the CDC definition of AIDS and ARC^‘5 (Appendix la). 
The goal of the AIDS definition was to encompass a syndrome of 
several features. The first feature is opportunistic infections (OI). 
They include the following: intestinal cryptosporidiosis; Pneumocystis 
carinii pneumonia (PCP); strongyloidosis beyond the gastrointestinal 
tract; toxoplasmosis in sites other than the spleen, liver, or lymph 
nodes; esophageal candidiasis; cryptococcosis beyond the lungs and 
lymph nodes; Mycobacterium avium or intracellulare (MAI) beyond 
the lungs and lymph nodes; cytomegalovirus (CMV) beyond the liver, 
spleen, or lymph nodes; disseminated herpes simplex virus; and 
progressive multifocal leukoencephalopathy (caused by the papilloma 
virus). A second feature of the AIDS syndrome is the occurrence of 
certain special neoplasms, such as lymphoma limited to the brain and 
Kaposi’s sarcoma (KS). Both OI’s and certain special neoplasms are 
believed to indicate underlying cellular immunodeficiency. In the 
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absence of other known underlying causes for the immunodeficiency, 
the CDC decided that these features are alone sufficient evidence of 
AIDS without a positive HIV titer. Other opportunistic infections and 
special neoplasms, when accompanied by a positive HIV titer, are also 
included in the case definition (see Appendix I). 
The goal of the CDC’s definition of ARC was to describe a 
prodrome of unexplained lymphadenopathy, rashes, fatigue, anorexia, 
oral candidiasis, weight loss, fever, night sweats, dyspnea, and diarrhea 
that frequently preceded AIDS, but did not always progress to it.^ 
Nevertheless, only demographic descriptions, diagnostic components 
of AIDS (i.e. PCP, MAI, KS, etc.) and a single yes/no category for 
"wasting syndrome due to HIV" were included in the CDC reporting 
form (Appendix lb) for ARC. No systemized approach for reporting 
symptoms was instituted. Thus, OI’s, secondary cancers, risk factors, 
and routine demographic information became the major variables used 
in studies considering the ultimate prognosis of AIDS. 
The Study by Kaplan et al. for Staging ARC: 
Working in conjunction with Gallo, Kaplan et al.^O developed a six 
stage system that was intended to reflect a progressive decrease in T- 
helper cell number from group 1 to 4. The scope of the system ranged 
from asymptomatic HIV infection (group 0) to AIDS (group 4). Group 
5 included patients who were positive for HIV while undergoing 




Important variables in The Kaplan stages of ARC included 
persistent lymphadenopathy, hypergamma-globulinemia, oral 
candidiasis and exaggerated infections (such as severe tinea versicolor 
of the skin; extensive molluscum contagiosum; prolonged ptyriasis 
rosea; severe tinea cruris; recurring condyloma accuminata; extensive 
secondary syphilis; or prolonged CMV). AIDS developed in 3 of 7 
subjects in group 3; and 4 of 32 patients in group 4 progressed to group 
6 disease. 
The Study by Haverkos et al.: 
After a survey searching for consensus among more than 80 
investigators, Haverkos et al.^l developed a seven-stage stratification 
which ranged from asymptomatic HIV infection to AIDS. Only stages 
6 and 7 involved full-blown AIDS. Stage 6 contained AIDS with only 
KS; and stage 7 contained AIDS with an OI, with or without KS. 
Important variables in the earlier stages of the Haverkos system 
included immune thrombocytopenic purpura, unexplained 
lymphadenopathy, low grade fevers or night sweats, minor 
opportunistic infections (such as thrush or herpes zoster), high fevers 
(>38.5° C or 101.3° F), watery diarrhea, and sustained weight loss of 
10% or more of body weight. Haverkos et al. hoped that their 
stratification would be useful for evaluating therapeutic trials, but did 




The Walter Reed System: 
Perhaps the best documented staging system for HIV infection is 
the Walter Reed (WR) Classification.^ its intent to reflect T cell 
function was stated as follows: 
This classification system is based on two central observations: 
the fact that the T-helper cell is the principal target cell of 
HTLV-III, and the clinical observation that the functional 
integrity of theT-helper cell determines the clinical 
presentation.*54 
The Walter Reed system contains seven stages that range from 
absence of HIV infection to full-blown AIDS. Important variables 
include asymptomatic HIV positivity, chronic lymphadenopathy, T- 
helper cells <400/mm*^, partial and complete anergy, and oral 
candidiasis. 
In a preliminary study of 39 sequential patients followed for 18 
months, Redfield et alP“ demonstrated that the patients in Walter 
Reed stages 3 to 6 had a "slow but progressive course to the next stage 
or death". A different group of investigators^*5 later substantiated this 
stratification by classifying 358 subjects and documenting progression 
of disease in 8 of 181 seropositive subjects in Walter Reed stages 2-5. 
These investigators, noting that severe thrombocytopenia was present 
in 19 cases, suggested that it be added to the WR staging. Redfield, of 
the Walter Reed staging, concurred.*^ 
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CPC Composite Classification: 
The most recent efforts at staging occurred when the CDC 
convened a panel that included Redfield (of the Walter Reed Staging) 
and Gottlieb (of the Haverkos et al. staging) as well as representatives 
from several branches of The National Institutes of Health. The panel 
jointly proposed a classification system (see Appendix II) to be used 
for purposes of reporting and surveillance. The new system 
incorporates most of the features of the previous systems.34 
Subsets of Variables: 
In several studies, subsets of the foregoing variables were identified 
as individually prognostic for the transition from a pre-AIDS state to 
AIDS. In the largest study, in a cohort of 1,835 homosexual men who 
were seropositive for HIV-^, multivariate analysis showed the 
following independent predictors: increased T suppressor 
lymphocytes, a low level of antibody to HIV, a high titer of CMV 
antibody, and a history of sexual contact with someone in whom AIDs 
developed. Predictors found in other, smaller studies were: T4 cell 
counts,36 number of homosexual partners,36 presence of oral 
candidiasis,37-38 elevated erythrocyte sedimentation rate,38 peripheral 
cytopenias,38 and previous history of herpes zoster.38 
Still other studies have directly examined the relationship between 
clinical presentation in AIDS/ARC and T cell function as reflected by 
T cell counts (T4, Tg, and T4/Tg ratios). The Multicenter AIDS 
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Cohort study (n = 2,646), using multiple logistic regression techniques, 
found certain ARC symptoms strongly associated with low T4 cell 
counts.^ The converse was not true, however: low T4 counts were 
not helpful in predicting clinical involvement. Fever, oral candidiasis, 
low hematocrit, and low neutrophil counts were strongly predictive of 
low T4 cell counts. Fatigue and low platelet counts were also 
correlated (although, less strongly).^ 
Lane^ studied 38 patients, of whom 17 presented with OI’s; 12 
with KS alone; and 9 with ARC. The mean number of T4 cells in these 
three groups respectively were 34/mm^, 231/mm^, and 703/mm^. 
Lane concluded that OI’s represent a subgroup of patients with a more 
severe immunologic abnormality than KS. He suggested that KS may 
represent an earlier manifestation of AIDS in patients predisposed to 
developing KS. 
Despite all of the efforts in classification, none of these staging 
systems was tested for predicting the survival of AIDS. Their main 
intent was to use clinical parameters, reflective of T cell function, in 
predicting which ARC patients were most likely to progress to 
AIDS.29'31 The predictive variables in these systems consistently 
included: demographic risk group characteristics,28,30-31,36-37 oi’s 
and secondary cancers/28,31-32,35 minor OI’s,30"36>39 
lymphadenopathy,30'36,39 orai candidiasis,^30-35,38-40 weight loss,30" 
31,33-35 diarrhea 50-31,33-35 fgygj-s 30-31,33-35,40 
night sweats,30-31,33,35 piatelets,30-31,33-35,-40 cytopenias,39-40 
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T cell counts,30-31,34-37 anergy530-31,34-35 ancj ]-ny titers.28,30- 
31,34-36 
Prognosis for Survival with AIDS: 
Four studies have considered overall mortality in AIDS. The San 
Francisco study by Moss et al.^l examined 168 reported cases of AIDS 
before May, 1983. The United Kingdom study^^ examined 168 
patients with AlDs reported to the Public Health Laboratory Service 
Communicable Disease Surveillance Centre between 1982 and June, 
1985. An earlier New York City study^ was subsumed in a later 
study^, which contained 5,833 AIDS patients reported during July, 
1981 to January, 1984. In all four studies, survival was calculated from 
time of diagnosis. For comparison here (see Appendix III) all survivals 
were converted to 30 day months and tenths of months (3 days = 0.1 
month). 
All four studies found KS to have the best prognosis, with median 
survivals ranging from 29.2 months^ to 21.0 months^. PCP had the 
worse prognosis in all studies, with median survivals ranging from 12.5 
months^ to 8.2 months ^3. The combination of KS and PCP had 
median survivals that ranged from 12.7 to 6.6 months44>42 Other OI’s 
also showed a wide range of medians: from 13.3 months^ to 
4.2 months^. Only the New York studies checked the combination of 
KS and other: 15.2 months,^3 10.8 months^; and PCP and other: 
10.3 months,^3 10.0 months^. (In both instances, "other" refers to any 

OI or neoplasm qualifying for the AIDS diagnosis, but not to PCP or 
KS). 
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The recent New York study^ examined several demographic 
factors (sex, race, ethnic background, age and risk group) in addition to 
diagnosis of OI or secondary cancer. Although age, race, risk group, 
and sex had prognostic significance, the effects were much smaller than 
those of particular disease manifestations (such as KS, PCP, MAI, 
etc.). The diagnostic manifestations were 4.6 times more predictively 
influential (accounting on the average for 56.3% of the excess risk) 
than the most significant demographic variable, age (which accounted 
for only 12.2% of the excess risk).^ The authors concluded: 
Ideally, a study of survival with AIDS would attempt to take into 
account all manifestations of the disease in each subject, the 
order in which the manifestations occurred, the intervals 
between occurrences or relapse, and the type of treatment used. 
Such detail is not available through routine methods of 
surveillance; however, our data suggest a broad spectrum of 
survival based on patterns of disease acquisition.44 
Functional Prognostic Stratification 
Lessons from Cancer Research: 
A great deal can be learned from the extensive experience of 
researchers studying prognostic staging systems for cancer. Feinstein 
and colleagues have consistently shown that the most effective 
prognostic staging systems include clinical manifestations as well as 
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paraclinical data and conventional anatomical staging 45-47 More 
recently these investigators also showed that the results of clinical 
staging tends to remain constant, but anatomical (or morphologic) 
staging is prone to the "Will Rogers effect".48 This effect occurs when 
diagnostic technologies cause a lead-time bias and a resultant 
morphologic stage migration. The lead-time bias occurs when new 
diagnostic technologies (e.g. computed tomography) detect tumors in a 
smaller or "earlier" condition than the same tumor would have been 
detected by more "primitive" technology (e.g. chest X-ray). The stage 
migration occurs when the staging is solely dependent upon 
morphology (e.g. presence or absence of tumor) rather than functional 
loss (e.g. increasing respiratory distress). The resulting improvements 
in survival rates do not reflect any real improvement in survival, but 
merely stage migration within an anatomical staging system. 
The same stage-migration effect might also be produced by 
paraclinical tests that are not ordered routinely. For example, after a 
particular test, such as a bone marrow biopsy, is found to have 
prognostic significance, the test may be performed more often than 
previously. With the increased testing, many asymptomatic patients 
with a bone marrow infiltrate, such as MAI, will be moved into a 
poorer prognostic category before they show signs of hematologic 
compromise or even suppressed peripheral counts. As in the Will 
Roger’s effect, the asymptomatic patients would migrate to a worse 
prognostic stage and survival rates would be falsely improve. 
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Conclusions from Prognostic Review: 
Experience in cancer research suggests that when staging systems 
depend on morphology alone, the results may become unreliable if the 
diagnostic tests become more sensitive or are performed more 
frequently than before. On the other hand, a system that depends on 
overt functional effects should not be affected by changes in 
technology, particularly if the functional effects are manifested in overt 
clinical findings and routine paraclinical data. In addition to 
consistency, such a system would be less expensive, invasive, and 
painful than a morphologic system requiring biopsy or radiologic scans 
with contrast media. 
The work reported in this thesis is an innovative attempt to develop 
the desired prognostic staging system for adult patients with AIDS. 
The system depends on routinely collected historical information, 
clinical manifestations and basic paraclinical data. Because of the 
relatively small number of patients under study, the results cannot be 
documented as a definitive staging system for AIDS. Nevertheless, the 
results show that the functional effects manifested by certain signs, 
symptoms, and paraclinical data offer a simple, effective, and clinically 
plausible system of prognostic staging. Further research at this 




MATERIALS AND METHODS 
Selection of Patient Population: 
The inception cohort in this study consists of all adult AIDS patients 
who were originally diagnosed or first treated at Yale New Haven 
Hospital (YNHH) during the period from October, 1980 (when the first 
YNHH case was identified) to April 20, 1987. The latter closing date 
was the time at which the roster of AIDS cases at YNHH had been 
most recently updated when this study began. The AIDS office at 
YNHH maintains the roster, reports new AIDS patients to the Centers 
for Disease Control (CDC), and administers an AIDS clinic with 
routine follow-up on all patients. 
The medical record of each patient listed on the roster was obtained 
and reviewed. To be entered in this study, each patient had to fulfill all 
of the following eligibility criteria (for a decision flow chart, see Figure 
1): 
1. The patient must have been diagnosed as having AIDS 
clinically in accordance with the WHO/CDC criteria3 4 5 of 
March 1986 (Appendix la). 
2. The patient must have been diagnosed while alive (i.e. 
not at autopsy alone). 
3. The patient must not be pregnant (pregnancy is known to 
affect immune response ana human investigation on 
pregnant patients is restricted). 
4. The patient must be at least 19 years old. 
5. Sufficient data must be available, including a reasonably 
complete history and physical examination, as well as a 
complete blood count performed within one month before 
zero time (as defined below). 

6. The patient must not have been immediately lost to 
follow up after zero time. 
Of the 156 patients listed on the roster for the cited time period, 39 
were ineligible: 3 patients’ records were unavailable or lost; 4 failed to 
meet the CDC criteria; 3 were not diagnosed until autopsy; 1 was 
pregnant; 12 were below 19 years of age; 10 had insufficient baseline 
data; and 6 were lost to follow up almost immediately after zero time. 
The remaining 117 patients form the inception cohort for this study. 
Selection of Zero Time (ZT): 
Zero time (ZT), the point from which all serial time intervals were 
measured for each patient, was determined in a stepwise approach in 
each eligible medical record (for decision flow chart see Figure 2). The 
first step was to find the date at which the patient would have first 
fulfilled the WHO/CDC criteria (of March 1986) for the diagnosis of 
AIDS. If that date occurred while the patient was being treated at 
YNHH, either as an inpatient or as an outpatient, and if there was 
sufficent data collected for an extraction, the day of definitive diagnosis 
was the date of ZT. If the patient was first definitively diagnosed 
somewhere other than YNHH or if the data at the first YNHH 
diagnosis were insufficient, zero time was the first date of YNHH 
admission (to AIDS clinic or inpatient services) after sufficient data had 
become available to fulfill the diagnostic criteria for eligibility. Patients 
with a "delayed" zero time (i.e. ZT assigned at some time after the 
patient first fulfill the criteria for an AIDS diagnosis, rather than on the 
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day of diagnosis) were given special identifications. Their results would 
later be analyzed separately to check for the possibility of prognostic 
differences between patients with "prompt" and "delayed" zero times. 
Extraction/Coding of Medical Record Data: 
The primary source of data was each patient’s medical record for 
both inpatient and/or outpatient status at YNHH. Additional 
information was sometimes obtained from the patient’s personal 
physician or from the AIDS clinic director or coordinator. In no 
instance was the patient or any member of the patient’s family 
contacted directly. 
The data for each patient were extracted in four general categories: 
demographic; clinical; paraclinical; and co-morbid. This taxonomic 
system, which had been used in previous prognostic studies at 
YNHH^"^“, and was designed to include all of the diverse types of 
data that had been reported as significant in previous AIDS research. 
The extraction form went through many different drafts before a 
final format was selected (as shown in Appendix IV). The extraction of 
data for each patient required a complete reading of the patient’s 
medical record and any available clinic notes. The process took an 
average of about four hours for each patient. 
After the first 76 extractions were completed, a special new form was 




records and for computer coding of extracted data. The form is shown 
in Appendix V, and the associated coding manual is shown in Appendix 
VI. Data from all previous extractions were transferred to the new 
form, and the last 42 medical records were all extracted directly onto it. 
The comments in the text that follows are confined to a discussion of 
pertinent major decisions made during the data extraction and coding 
(details of the coding techniques are described in Appendix VI). The 
extraction form was organized around the ZT date and the patient’s 
status at zero time. Sections were provided for data concerning the 
"pre-ZT" interval that preceded ZT; for the ZT admission or clinic visit, 
labeled "ZT"; and for the "post-ZT" interval thereafter until the patient’s 
death or the last date of follow up. 
The extracted demographic data included age, race, sex, and 
documented risk factors for AIDS, such as homosexuality, drug abuse, 
multiple blood transfusions, and sexual partners with AIDS. In the 
chronologic account of clinical and paraclinical manifestations of AIDS, 
special attention was paid to severity and timing of ARC/AIDS 
symptoms, and to co-morbid states such as endocarditis or documented 
alcohol abuse. Each extraction included a detailed account of the ZT 
history and physical examination, as well as routine laboratory findings 
(complete blood count, sedimentation rate, chest X-ray, etc). The post- 
ZT interval ended with the date of death or last follow up, and the 
corresponding data included autopsy findings, and major post-ZT 
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clinical events as well as clinical decisions, such as initiation of AZT 
therapy or a do-not-resuscitate order. 
Follow up information was obtained from inpatient charts, AIDS 
clinic charts, or private physicians. An assessment of survival status for 
each of the 118 patients was made as of December 31, 1987, which was 
the closing date of the research. 
Analytic Methods: 
For data analysis, the patients were divided into two sets. One set, 
called the development set, contained the first 76 patients eligible for 
the study. This development set was analyzed to form a prognostic 
classification system. The second set, called the challenge set contained 
the next 42 consecutive eligible patients. The challenge set was used for 
a validating test of the previously developed prognostic staging system. 
The challenge set data were not analyzed until the staging system was 
ready for testing. 
After the test was completed (with successful validating results), all 
the data were then combined and re-analyzed to see whether any 
further cogent prognostic factors might be identified. 
The prognostic staging system was developed by a "targetted cluster" 
method of stratification.^ Conventional statistical methods of 
multivariable analysis using the proportional hazard function (Cox 
regression) procedure were then carried out as confirmation and to 
check whether any important variables had been overlooked. 
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Data Processing Methods: 
In order to ensure accuracy, the coded data were double entered into 
the computer, and verified using a program which compares pairs of 
records character by character. 
Computerized data analysis was performed using the SAS (Statistical 
Analysis System)54-55 collection of packaged statistical procedures, 
version 5, run under MVS on the IBM 4341 computer at the Yale 
Computer Center. The specific statistical procedures employed were: 
PROC FREQ-for univeriate frequencies, crosstabulations with 
specific survival targets, contrasts of distributions between the two 
population and associated xz and Fisher’s exact tests; 
PROC UNIVARIATE-to generate distributional data for 
dimensional variables, and median survival times within subsets of data; 
PROC T TEST-to test the baseline differances for dimensional 
variables between development and challenge groups; 
PROC CORR--to assess the correlations of survival time with 
dimensional variables; 
PROC LIFETEST-to generate life table estimates of survival for 
the prognostic strata and to test that calculated curves were statistically 
different from each other using the Wilcoxon test for homogeneity over 
strata; 
PROC PHGLM-to generate Cox proportionate hazard models. 
The Cox analyses were conducted using a stepwise algorithm, with 




Data analysis proceeded in three main phases. Phase one was 
concerned with the development set (i.e. the first 76 consecutive 
eligible patients.) This information was used to explore and arrange 
the prognostic variables into a staging system. In phase two, data from 
the challenge set (the next 42 eligible patients) were used to test and 
validate the staging system. In phase three, the two data sets were 
combined for further analysis and evaluation. 
Phase One: Analysis of Development Set 
The analysis of data for the development set began with a simple 
statistical overview of each variable for which data had been collected. 
Each baseline categorical variable (expressed as binary or ordinal 
ratings) was cross tabulated with survival at 4, 6, 8, 10, and 12 months 
(Tables 1-6). A particular category was identified as potentially 
important if the data contained 4 or more subjects within that category, 
and if the comparison with other categories in the same variable 
showed a consistent survival gradient over the 12 month period. A 
category that contained too few patients was also retained as 
potentially important if the category could be logically combined with 
other similar categories and if the combination had a distinctive 
prognostic gradient. Dimensional variables were analyzed by linear 

correlation with survival (Table 7). Dimensional variables were 
regarded as potentially important if the correlation was statistically 
significant (p<.05). 
30 
For clarity in this presentation, no statistical numbers will be cited 
in the text for the initial elemental data, which are all listed in Tables 
1-7. In the description that follows, potentially important variables will 
be discussed according to their data type, and their apparent univariate 
impact on survival. The location of the Table with the corresponding 
data is noted for each variable. The citations of negative and positive 
predictors are listed according to trends in the data, without 
calculations of statistical significance, which are reserved for the 
combined categories discussed later. The associated survival was 
reduced by a negative predictor and increased by a positive predictor. 
Note that, at this stage, all variables that fulfilled the above criteria 
for "potential significance" were included whether or not they seemed 
to make "clinical sense." Later on these variables will be subjected to 
more rigorous clinical and statistical filtration. 
Demographic Data/Table 1: Negative predictors: 
Hispanic race and homosexual male. Positive predictors: 
heterosexual exposure, and exposure by blood transfusion. 

AIDS Diagnostic Category/Table 2: Negative predictors: 
MAI, Cryptococcus, KS, and other. Positive predictors: 
PCP and Candida esophagitis. 
Historical Data/Table 3: Negative predictors: weight loss, 
constant diarrhea, KS, any Herpetic lesions, any 
encephalomeningeal symptoms (stiff neck, new seizures, 
severe lethargy/confusion, and photophobia), any "other" 
neurologic symptoms (dysarthria/aphasia, paralysis, and 
dementia). Positive predictors: enlarged lymph nodes. 
Co-morbid Data/Table 4: Negative predictors: previous 
diagnosis of endocarditis, and previous suicidal 
gestures/attempts. Positive predictors: smoking history of 
> 1 pack per day for _> 10 years, and history of gonorrhea. 
Physical Exam Data/Table 5: Negative predictors: oral 
thrush, retinal abnormalities, encephalomeningeal signs 
(stiff neck, new seizures, severe lethargy, and/or 
photophobia), and other neurologic signs (dysarthria/ 
aphasia, paralysis, dementia). Positive predictors: 
detectable lymphadenopathy. 
Paraclinical Data/Table 6: Negative predictors: positive 
serologies for CMV, cavitary lesions on chest X-ray, 
lobular infiltrate on chest X-ray and ring-enhancing lesions 
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on computed tomography of the head. Positive predictors: 
normal or "partial" result on anergy test. 
Dimensional Data/Table 7: Negative statistically 
significant correlations: none. Positive statistically 
significant correlations: hematocrit, lymphocyte count, 
and duration of diarrhea. 
One pertinent feature of Table 7 was that T cell counts were not 
significant in linear correlation with survival (P <_.05). T4 counts came 
closer to significance than T4% (percentage of T4 cells among total 
lymphocytes) or T4/Tg ratio (T4, P = 0.2; T^%, P = 0.8; T4/T8, P = 0.4). 
The expected correlation of survival with T cell counts was probably 
not found because of sparse data. Only 28/76 (37%) of the 
development set patients had their T4 cells measured. A separate 
problem in the T cell measurments was their timing. Even when done, 
the measurement was seldom obtained at or near zero time. In the 
analysis of data, we used the T cell measurements that were closest to 
ZT, but their timing was often substantially earlier or later than ZT. 
For these reasons-lack of significance in linear correlation, small 
numbers of patients, and temporal discordance--T cell count was not 
included in our staging system. 

Ordinalization of Dimensional Data and Formation of Prognostic 
Unions 
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In the next step of the phase one analysis, we gave further attention 
to variables that were considered prognostically promising, either 
because of previous clinical beliefs or because of the results of our 
initial univariate analysis. 
Because we wanted to develop a staging system based on categories, 
the dimensional variables were "ordinalized" into categorical groupings 
as shown in Table 8. Several boundaries for these groups were 
explored during the process of ordinalization. The final choices 
depended on both the particular data being analyzed and on 
conformity with reasonable clinical customs. Table 8 shows a summary 
of the most striking results found with the ordinalized categories of the 
dimensional variables. No P values are cited for this preliminary 
exploration of survival gradients. Tests of significance will be reserved 
for the final staging evaluation. 
The power of ordinalization and binary partitions is particularly 
well shown for room air arterial pCU and WBC’s. Although pCU did 
not have a striking statistical effect when linearly regressed against 
survival, a marked prognostic gradient is shown in the binary partition 
(4 month survival was : 4/12 (33%) with pO2<_50%; and 43/64 (67%) 
without)(Table 8). White blood cell count (WBC) was also 
unimpressive in linear regression but showed a marked prognostic 
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difference in patients with WBCs < 2,500/ml and in those with higher 
values (4 month survival: 1/6 (17%) vs. 46/70 (66%)). 
As might be expected from the significant regression with survival, 
hematocrit categories also showed a marked difference in survival. (4- 
month survival was: 10/22 (45%) for patients with hematocrits below 
30 vs. 37/54 (71%) for hematocrit of 30 or above). 
Platelet counts are often reported in ordinal categories (such as 
"low") by the laboratory at YNHH. The "low" designation, which 
represents counts below 140,000/ml, was prognostically important. 
The 4-month survival was 4/11 (36%) for patients with low platelet 
counts and 43/65 (66%) for those with higher values. 
The next step was to combine the ordinalized dimensional data and 
the important categorical variables into clustered unions. In the first 
set of analyses an attempt was made to combine categories that had 
nadir and zenith survival results (Table 9). Past history of ring 
enhancing lesions on head CT, cavitary lesions on chest X-ray, and 
endocarditis were put into unions because each category seemed to 
reflect a nadir prognosis. (Respective 4-month survival rates were: 
1/4 (25%); 0/4 (0%); 2/6 (33%).) These three variables formed a 
union with a 4-month survival of 3/11 (27%). The zenith union 
comprised patients with blood transfusion as their risk factor or with 
j> 150,000 lymphocytes per ml. (4-month survival: 5/5 (100%) and 
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11/14 (79%), respectively). The union of this set of categories 
produced a zenith survival of 9/9 (100%) at 4 months. 
Construction of "Functionar Unions 
We were concerned that the variables contained in the zenith and 
nadir unions were largely either morphologic (such as ring enhancing 
lesions on head CT and cavitary lesions on chest x-ray) or demographic 
(such as blood transfusion exposure). Because morphologic and 
demographic attributes may not directly reflect the functional severity 
of a disease’s impact, the next step in the phase one analysis was to 
form functional groupings (or unions) of variables that might indicate 
the known pathologic processes of AIDS. The four unions that we first 
explored were: respiratory failure; neurologic failure; bone marrow 
failure; and nutritional failure. 
Several variables were considered for inclusion under respiratory 
failure: degree of reported dyspnea (Table 3), respiratory rate (Table 
7), and p02 (Table 8). Of these, only p02 showed a real difference in 
survival. Thus pO2<_50 mm Hg (or hypoxemia) became the pertinent 
prognostic variable for respiratory function. 
For neurologic compromise, the main functional variables were 
those of neurologic symptoms and signs. These variables were 
contained under the headings of encephalomeningeal symptoms, other 
neurologic symptoms, encephalomeningeal signs, and other neurologic 
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signs. In preliminary analysis of data in Tables 3 and 5, symptoms were 
superior to signs for prognosis because more patients had symptoms 
than documented signs although nearly all patients with signs also had 
symptoms. Thus all symptom manifestations under the headings of 
encephalomeningeal symptoms and other neurologic symptoms, except 
"other", were incorporated into a functional union of neurologic 
deficit. The manifestations included a history of stiff neck, new 
seizures, lethargy or confusion, photophobia, dysarthria/aphasia, 
paralysis, or dementia. This union had a 4-month survival rate of 7/19 
(37%) in patients with nerologic deficts vs. 40/57 (70%) in patients 
free of such deficits. 
Bone marrow compromise/failure was determined from 
paraclinical data because patients did not routinely demonstrate the 
traditional clinical manifestations of bleeding, petechiae, etc. The 
complete blood counts collected on all patients avoided the selection 
bias that might arise in technologic decisions such as getting a CT scan 
for certain patients but not for others. The binary partition values of 
hematocrit (<30), platelets (< 140,000/ml.), and WBCs (< 2,500/ml.) 
(Table 8) were then grouped into a union of cytopenias (Table 8). Any 
one cytopenia qualified a patient for inclusions in the union. Because 
two or more cytopenias seemed ominous, such patients were placed in 
a separate category of bone marrow failure (4-month survival rates 
were: 0 cytopenias = 35/48 (73%); l-of-3 cytopenias = 9/18 (50%); 2 
of 3 cytopenias = 3/10 (30%). At 8 months of survival time, all of the 
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10 patients with 2 of 3 cytopenias were dead, contrasted with only 56% 
of those patients without cytopenias. 
Because weight loss and diarrhea occur commonly in AIDS 
patients, a concerted effort was made to explore variables that might 
reflect compromised nutritional function. The variables analyzed for 
this purpose were: reported weight loss, percent weight lost below a 
standardized normal weight, average weight, admission weight, serum 
albumin, and duration and severity of diarrhea (Table 10). Because 
weight status, and features of weight loss had been poorly reported or 
recorded, no reliable relationship could be established for the weight 
variables. The only promising prognostic variable in the "nutrition" 
group was constant diarrhea. 4-month survival was 7/18 (39%) for 
patients with constant diarrhea , and 39/57 (68%) for those without 
(Table 10). In the 18 patients with constant diarrhea, only four had had 
diarrhea for at least a month. The survival gradient, shown in Table 
10, was not particularly striking over 12 or 4-month durations. 
Combinations of degree of diarrhea and weight loss were explored as 
well as combinations of diarrhea and low serum albumin. None of the 
combinations seemed prognostically important. Consequently a union 
based on "nutritional failure" was not included in the staging system. 
The many other variables individually explored in the early analyses 
were not included in any unions. Their prognostic gradients or 
numbers of patients were too small; or the variables did not reflect 

functional impairment, some of these variables were set aside for 
further evaluation in the entire data set after the challenge set tests 
were completed. 
Final Staging in Phase One 
The three successful functional unions: hypoxemia (p02_<50 mm 
Hg), neurologic deficit (any one of the following: stiff neck, new 
seizures, severe lethargy/confusion, photophobia, dysarthria or 
aphasia, partial or complete paralysis, or dementia), and cvtopenias 
(any one of the following: hematocrit <30, white blood cell count 
< 2,500/ml, or platelet count < 140,000/ml) were then arranged into 
prognostic stages (Table 11). 
Stage I consisted of patients who had none of these functional 
deficits. Stage II consisted of patients having any one of the functional 
deficits, but no more than one cytopenia. Stage III patients had at 
least two of the three cytopenias. The survival rates at 4 months in the 
three stages respectively were 25/28 (89%); 19/38 (50%); and 3/10 
(30%) at 6 months. The corresponding median survival times were 
11.2, 3.9, and 2.3 months, respectively. Figure 3 shows the life table 
analysis of the developmental group by stages. 
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Phase Two: Comparison of Development and Challenge Sets 
With the staging system developed, phase two was devoted to 
checking its performance in the challenge set of 41 patients. The 
analysis of the challenge set requires some additional explaination 
because many members of the challenge set had their zero times in 
1987, and (at the time of this analysis) had not yet had the opportunity 
to live 12 months after zero time. All 41 members of the challenge set 
have been followed for a minimum of 6 months but when 8, 10, and 12- 
month survival rates are cited for the challenge set, some patients will 
be "censored", because they have not yet been followed that long. 
When censoring occurs, it is noted with an asterisk and footnote in all 
pertinent tables. 
For the same reasons, some of the median survival times are 
conservative figures. They were determined from the latest duration of 
survival, and might be lenghtened as certain patients have the 
opportunity to survive longer. These conservative citations are noted 
in bold print and with appropriate footnotes whenever they are 
displayed. 
For the sake of direct comparison with the developmental set, only 
4 and 6-month survivals will be reported in the text. Cited gradients 
will be chosen to bset illustrate the particular observation. As in the 
phase one results, pertinent tables are indicated in parenthesis. 
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In demographic characteristics and in AIDS diagnostic components 
(Tables 12- 13 vs. Tables 1-2) the development and challenge groups 
are quite similar. Their only major dissimilarity (by t-test) is in the 
number of Hispanic subjects (15 subjects in the developmental group 
and 1 in the experimental, P<.05). The two groups were not 
significantly different in 4 or 6-month survival rates. 
Validation of Staging System 
Table 14 shows the results of the challenge set partitioned into the 
proposed staging system. The results show the same prognostic 
gradients that were found in the development set with 4-month 
survival rates of: I, 11/15 (73%), II, 8/19 (42%), and III 2/7 (29%). 
Median survival times were 7.2, 1.6, and 0.7 months, for stage I-III 
respectively. (Note that the median for stage one is a conservative 
estimate due to censoring.) Figure 4 shows the life table analysis of the 
challenge set and offers a visual display of the prognostic gradients. 
In contrast, the nonfunctional unions were not effective forecasters 
in the challenge set (Table 15). The previous "nadir" set actually 
reversed itself and did better than patients without its attributes (6- 
month survival rates: 6/10 (60%) for nadir and 10/31 (32%) for non¬ 
nadir subjects). Two of the three component variables in the nadir set 
lost their negative effect. The results in Table 15 show ring enhancing 
lesions on head CT: 6-month survival 12/5 (40%) vs. 14/36 (39%), and 
history of endocarditis: 6-month survival 3/4 (75%) vs. 13/37 (35%). 
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Only one patient in the challenge set had a cavitary lesion on chest x- 
ray. 
The zenith set fared better than non-zenith set subjects in the 
challenge set group. 6-month survival rates were: 67% vs. 34% in non¬ 
zenith patients, but only half of the component variables in the zenith 
set remained as positive predictors in Table 15, blood transfusion risk 
still predicted longer survival (only 2 subjects, 6-month survival: 1/2 
(50%) vs. 15/39 (38%) in non-transfusion risk subjects). The high- 
lymph patients actually fared worse than those with lower values (6 
month survival 5/10 (50%) for high lymphs, 10/30 (33%) for those 
without). 
Thus, the non-functional variables and unions (Table 15) that had 
been sugested by the development set did not remain prognistically 
effective in the challenge set. On the other hand, the challenge set 
confirmed the prognistic gradients previously found in the functional 
variables and unions (Tables 14 and 16). 
Phase Three: Combination of Data Sets 
After the staging had been validated in the challenge group, the two 
data sets were combined for descriptive purposes and to provide a 
larger group for certain methodologic tests. The Tables 17-23 show the 
elemental data for all 117 patients previously listed only for the 
development set (Tables 1-7). These are included for descriptive 
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completeness, but demonstrate no new phenomona and will not be 
discussed. 
Examination of Patients with "Delayed" Zero Time 
Table 24 is addressed to a previously mentioned concern about 
patients with a "delayed" zero time. In some patients, ZT was the date 
of their first definitive AIDS diagnosis at YNHH, whereas other 
patients, for whom AIDS had originally been diagnosed elsewhere, 
were assigned ZT for the date of their first "admission" to the clinic or 
hospital of YNHH. The latter patients were included in the cohort to 
augment its numbers, but we were concerned that the "delayed-ZT" 
group might have different survival patterns from those of the 
"prompt-ZT" group. 
In Table 24, the patients are listed according to the three main 
prognostic stages, but are divided into the groups with prompt and 
delayed zero times. The subtotal results for the two ZT groups show 
identical median survival times (5 months) and almost identical 
survival rates (prompt ZT/delayed ZT) at 4 (58%/58%), 6 
(44%/42%), 8 (34%/31%), 10 (24%/22%), and 12 (22%/16%) 
months. The total results thus appear to justify the combination of the 
two ZT groups into a single cohort. 
On the other hand within the individual stages, some interesting 





and III. For the prompt-ZT group, the survival statistics are quite 
similar in stages II and III, whereas the delayed-ZT groups have a 
markedly different survival pattern in these two stages. Compared 
with the prompt-ZT group, patients in the delayed-ZT group have 
better survivals in stage II and worse survivals in stage III. The 
I 
distinction may arise because the disease is less virulent in patients 
who can remain in Stage II despite a delay in ZT, and more virulent 
(or closer to death) in stage III patients whose survival duration is 
shorted by assignment of a delayed ZT. 
The distinction should also be borne in mind when this staging 
system is applied in prognosticating for future patients. If zero time is 
promptly established, the most significant survival gradients may be 
between Stage I and the other two stages, rather than among all three 
stages. 
Appraisal of AZT Therapy 
Another concern in the phase three analysis arose because the new 
drug, azidothymidine had become available as a possibly effective 
treatment for AIDS. This drug was received by 1 patient in the 
developmental set and by 7 patients in the challenge set. All 8 patients 
were alive at the date of last follow-up. Stage I contained 4 AZT 
patients: 1 alive at 12 months, 1 alive at 10 months, and 2 alive at 8 
months. Stage II contained 3 AZT patients: 1 alive at 12 months, 1 
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alive at 10 months, and 1 alive at 8 months. Stage III contained 1 AZT 
patient who was alive at 8 months. 
Although the results at first appear encouraging, the effectiveness 
of AZT is difficult to analyze from these data. Not only are the 
numbers small, but AZT was not given at zero time. Because AZT was 
started after zero time in these patients when they might have altered 
their clinical stage. A patient in stage II at ZT, because of a low white 
count or hematocrit might have had spontaneous improvement after 
ZT before the AZT was initiated. For these reasons, the AZT results 
in this population cannot be analyzed. The apparently high survival of 
all 8 patients may be due to AZT, but may also arise from selection 
bias in the way the patients were chosen for AZT therapy. Decisions 
about the efficacy of the drug would require further study for of a 
larger group of patients, classified into appropriate stages when AZT 
therapy was initiated. 
Overall Staging in Comparison with Other Predictors and those Used 
by Rothenberg et al. 
Table 28 and Figure 5 show the final results of the three functional 
stages for the entire population of 117 patients. The overall median 
survivals in the stages were I: 9.2 months; II: 3.5 months; and III: 2.1 
months with a total median survival of 5.0 months (note that the stage 
I median is conservative due to incomplete follow up). The three 




For contrast, Table 29 compares the survival results of these three 
functional stages, with the results of the prognostic variables used by 
Rothenberg et al.44 as noted in the CDC reporting forms. For each 
cell in Table 29, the numbers show N (the size of the group), the 6- 
month survival rate, and the median survival in months. The table 
clearly shows that the stages discriminate survival rates much more 
strongly than the demographic and morphologic-etiologic variables 
examined by Rothenberg et al. 
To demonstrate the impact on survival of competing variables, we 
used Cox regression. In the regression analysis the three group staging 
system was entered as one variable, and the other entries included: the 
nadir and zenith set variables, MAI, and Candida esophagitis, and the 
Rothenberg et al.44 demographic and diagnostic component variables. 
None of these variable were contained in the three stages but had 
looked promising during analysis. The results, which show the 
variables that emerged in their order of importance in the regression 
were as follows: 
1. Staging System p< 0.00001 R = 0.166 
2. Constant Diarrhea p = 0.0008 R = 0.109 
3. Candida Esoph. p = 0.0192 R = 0.067 
4. Hispanic Race p = 0.0375 R = 0.055 
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The Cox regression analysis was then repeated, with the staging 
system eliminated as a single variable, and replaced by its component 
elements. All the additional variables were entered into the analysis as 
before. The sequence of important variables was as follows: 
1. Bone Marrow 
Failure 
p = 0.0001 R = 0.129 
2. Low p02 p = 0.0003 R = 0.121 
3 Neurologic 
Manifestations 
p = 0.0019 R = 0.100 
4. Constant Diarrhea p = 0.0010 R = 0.107 
5. Candida 
Esophagitis 
p = 0.0121 R = 0.075 
6. Hispanic Race p = 0.0396 R = 0.054 
7. High Lymphocyte 
Count 
p = 0.0300 R =-0.059 
(In the Cox results, a posititve R value implies a negative effect on 
survival.) Thus, high lymphocyte count, with a negative R value, was a 
positive predictor, although its effect was relatively small when 
compared with the other cited variables. 
In both sets of Cox regression analyses, the staging system or its 
component elements was much more prognostically effective than any 
of the variables not included in the staging. Only one functional 
variable, constant diarrhea, that was not included in the staging, 
showed an impressive effect (with R values >..05). This variable should 
be considered as an additional possible component of the functional 
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staging when its value can be confirmed in larger numbers of patients 
than were available for this analysis. 
Summary 
In summary, the functional staging system developed in a single set 
of subjects was substantiated in a separate challenge set, as well as in 
comparison with predictor variables used in the most authoritative 
previous prognostic study. The results clearly demonstrate that 
functional variables are superior to demographic or morphologic- 
etiologic variables in predicting survival of patients with AIDS. The 
main functional variables were indications of hypoxemia, neurologic 




Three issues remain for discussion: 1. Comparison of this study’s 
results with those of previous studies, and possible explanations for the 
differences; 2. Possible problems in this study; and 3. Potential 
applications for the proposed staging. 
Review of Previous Studies of Predictive Variables 
In previous research with AIDS, two types of prognoses had been 
evaluated. In one type of study, the prognostic transition was from 
ARC to overt AJDS-a transition not assessed in this research but 
potentially pertinent to it. The second type of prognostic study was 
aimed at the same goal as the current research: predicting survival 
among patients having overt AIDS. 
Functional Variables Vs. Non-functional Variables: 
An interesting finding in the prognostic transition from ARC to 
AIDS was the proposed importance of what we have called 
"functional" variables: lymphadenopathy, weight loss, diarrhea, fevers, 
night sweats, platelets, hematocrit, lymphocyte count, white blood cell 
count, T cell counts, and anergy.~8-40 jn studies of survival among 
patients with overt AIDS, however, very few of these functional 
variables were examined. The analysis was focused solely on 
demographic or morphologic-etiologic variables: sex, race, age, risk 
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group, and diagnostic components (i.e. PCP, KS, MAI, etc.).41_44 The 
current results, showing the powerful prognostic impact of functional 
variables (hematocrit, platelets, white blood cell count, pC>2, 
neurologic manifestations, and diarrhea) do not require explanation or 
reconciliation with these former studies, because the functional 
variables were not included in the previous studies of survival. 
Another important feature of previous studies is that none of their 
prognostic data were taken directly from the patients’ medical records 
(as in the current research). Instead, the previously analyzed 
information came from infectious-disease reporting forms 41-44 (see 
also Appendix lb) that included only morphologic-etiologic data (such 
as AIDS diagnostic components) or demographic data. The 
demographic-morphologic-etiologic variables make no distinction 
between patients who are symptomatic or asymptomatic, and between 
those who have major functional deficits or none. By emphasizing and 
classifying the functional consequences of AIDS, we were able to 
distinguish major prognostic gradients despite the statistical handicap 
of working with a relatively small number of patients. 
Immunologic Functional Variables: 
Because AIDS is an immunologic disease that selectively attacks T4 
lymphocytes,^ previous investigators have assumed that "the functional 
integrity of the T4 cell determines clinical presentation."^4 Three 
variables measured in the present study-T4 cell count, anergy, and 
lymphocyte count-might have been reasonably expected to reflect 
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functional integrity of the T4 lymphocyte. In fact, these variables were 
found to be individually significant in previous studies^O'34 of the 
transition from ARC to AIDS. Yet none of these variables were 
included in our staging system. Each variable, and our reasons for 
excluding it, will be discussed separately. 
T/| Lymphocyte Count: 
T4 cell count would appear a promising variable. It is, after all, a 
direct measure of the presence of T4 cells. Nevertheless, it could not 
be included in our staging because T cell counts were not done 
routinely, and the relatively few that were done, were not done at zero 
time. Only 28/76 (30%) of the development set and 3/41 (7%) of the 
challenge set ever had T cell counts done. Almost none of the counts 
were done on or near the patient’s ZT, and many counts occurred were 
6-12 months before or after ZT. Thus, the T4 values could not be 
included in our staging The two main reasons were the potential for 
selection bias when decisions were made to get the T-cell test for some 
patients but not others; and also the ineligibility ("off limits") feature of 
information obtained either after zero time, or too early before ZT to 
be pertinent for a ZT classification. 
Nevertheless, during certain Cox Regressions of the entire data set, 
the T4 cell count emerged as a significant prognostic variable. When 
T4 count was compared as a single variable with the staging system as a 
single variable in the 31 uncensored patients with T cell counts, the 
staging emerged first (X^ = 9.84; P = 0.0017; R = 0.232) and T4 count 

emerged second (X“ = 5.56; P = 0.0183; R = 0.156). Thus, even among 
the 31 patients for whom T cell tests were recorded, the staging system 
was prognostically more effective than the T-cell counts. 
This distinction is especially noteworthy with respect to costs.^4 
The routine paraclinical tests in our staging (ABG + CBC 
+ differential + platelet count) cost a total of $43.45, whereas a single 
T cell study costs $142.50. Another important distinction is that the 
data used in our staging came from tests that are done in the course of 
routine patient care, whereas T cell tests are not routinely required 
and their use in prognostic staging would substantially increase the 
routine costs of AIDS patient care. 
Anergv: 
Anergy failed to show prognostic value in this study, possibly 
because of small numbers. Only 31% (34/117) of the patients had 
anergy panels placed and read. The 6-month survival rates in these 34 
patients showed an impressive prognostic distinction. Of those with 
normal readings or only partial anergy, 75% (6/8) were alive at 6 
months compared with 36% (9/26) of those with complete anergy. 
When compared simultaneously with the other variables in the Cox 
regression analysis, however, anergy was not significant, perhaps 
because of covariance and small sample size. The prognostic role of 
anergy should be reappraised in future studies containing larger 




In contrast to T4 cell counts and anergy, lymphocyte counts were 
not handicapped by small sample sizes. The counts were available in 
97% (114/117) of the patients. Although lymphocytes initially seemed 
important as an isolated variable, they emerged as only weakly 
predictive because they were found to co-vary with a strong predictor, 
hematocrit. 
Another reason for the prognostic weakness of lymphocyte counts 
may be that they are low in almost all patients with AIDS. (The 
median count for all 117 patients in our series was 533.) For 
measurements that are almost all at one extreme of a normal Gaussian 
distribution, the laboratory tests themselves may not provide an 
effective differentiation of the extreme values. The results may then 
show little prognostic discrimination, despite their diagnostic 
importance. 
Furthermore, because HIV is known to selectively attack 
lymphocytes, a lowered lymphocyte count might well be prognostic^ 
for the transition from ARC to AIDS, but the count may be too low 
for further clinical distinctions after AIDS has become overt. In 
contrast, other cytopenias-such as low hematocrit, WBC’s or platelets- 
-may be more accurate reflections of bone marrow infiltration and 
compromise, a secondary process associated primarily with MAI.53 
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Possible Problems in this Study 
Several problems may arise from the methodology of this study. 
They include: definition of zero time (ZT), the effects of AZT 
therapy, reversibility of staging, changes in prognosis as physicians 
become more adept at treating AIDS, and the limitations of a medical 
record review. 
Definition of ZT: 
The comparison of prompt and delayed zero-time groups (Table 
28) shows both encouraging and discouraging results. On the one 
hand, the total results in these two groups seemed to show almost 
identical prognoses. The two groups were therefore reasonably 
combined into a single cohort. On the other hand, after a staging 
system was developed for that cohort, the delayed zero-time group had 
a more striking survival gradient between stages II and III than the 
prompt group. 
The emergence of this distinction helps demonstrate the 
importance of prognostic staging for patients with AIDS. The 
differences between the prompt and delayed zero-time groups became 
apparent only after the staging was imposed. The differences also can 
shed light on how the staging system might be improved in the future. 
The delayed ZT patients have obviously already "survived a round". 
After their initial diagnosis elsewhere, they lived long enough to be 
admitted to YNHH. All the patients who would have died elsewhere 
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during their 1st hospital admission for AIDS did not live long enough 
to reach YNHH and become a delayed-ZT member of our cohort. If a 
patient who survives a first admission is thereafter more likely to live 6 
months than a patient who has not yet passed the test of a first 
admission, then the delayed ZT patients could be expected to live 
longer than prompt-ZT patients even when in the same composite 
clinical stage. At the other end of the spectrum, however, delayed-ZT 
patients with Stage III severe illness may be less likely to recover and 
may die sooner than prompt-ZT patients in the same severe stage of 
disease. 
The prognostic effect of pre-therapeutic duration of disease within 
patients in the same stage should be checked in the future when larger 
numbers of patients are available. In the meantime, however, users of 
the current prognostic system should bear in mind that its major 
discrimination is between Stage I and the other two stages. Whether 
Stages II and III continue to create distinctive prognostic differences 
remains to be confirmed in future research. 
Effects of AZT Therapy: 
The preliminary results of AZT therapy among the 8 patients in this 
study are attractive but cannot be interpreted. The numbers are too 
small and the treatment was given after their zero-time status. There is 
a strong probability of post-ZT selection bias, because AZT was given 
only to patients who were able to survive and recover somewhat from 
their first AIDS diagnostic infection or cancer. The only conclusion 
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that can be reached about AZT therapy is that it alone has not been 
conclusively shown to improve our survival results. 
Reversibility of Stages: 
The possibility that AIDS patients might reverse their staging (i.e. 
go from stage II to stage I) deserves more discussion. During the 
extraction of the medical records we noted that certain post-ZT events- 
-such as development of adult respiratory distress syndrome, recovery 
from a cytopenia, or a response to trimethoprim-sulfamethoxazole 
(Bactrim) therapy-seemed to have an important influence on survival. 
Because we were trying to predict survival from a defined point in 
time, our study design precluded inclusion of such post-ZT events. In 
future studies, valuable results might emerge if patients are "restaged" 
after susequent but significant prognostic events may prove productive. 
Improved Prognosis with Improved Treatment: 
Another concern about the timing of this study is the possibility that 
prognosis will improve as physicians become more adept at treating 
various opportunistic infections. Despite this possibility, the challenge 
group, which represented a more recent patient population than the 
development group in this study, actually had a similar survival 
patterns. This result is in contrast to what was found by Rothenberg et 
al.44 in New York City. In that study, cumulative probability of one 
year survival with PCP increased from 18.2% (in 1981) to 48.2% (in 
1985). However, most 78% of the secular increase in probability of 
survival (from 18.2%-41.7%) occurred during the period from 1981 
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to 1983. Only 13/117 (11%) of the patients in our study had zero time 
during the 1981-1983 period. The remaining patients were diagnosed 
after 1983-a secular interval for which Rothenberg et al. found much 
less of a secular increase (from 41.7-48.2%) in the survival rates.^4 
Limitations of a Medical Review: 
Medical record reviews present special problems in data 
collection.49'5- The extractor can only collect data that were 
recorded, and the accuracy of the extracted data will be limited by the 
accuracy with which the information was originally inscribed. Further, 
the data are subject not only to observer bias occurring during the 
original doctor-patient interchanges that led to the recorded 
information, but also to bias in the person extracting the record. 
Nevertheless patient records can be and have been invaluable sources 
of information, particularly when standardized methods^"^ are usecj 
for maximizing the consistency and accuracy of the extraction process. 
Since a review of the medical record is used both in research activities 
and in communication among clinicians, the information is particularly 
applicable for the purpose of clinical staging. 
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Potential Applications for the Proposed Staging System 
Aside from its prognostic discrimination, the new staging system has 
the major advantage of being simple, non-invasive, and inexpensive. 
The staging information does not require special forms of imaging, 
invasive procedures, or expensive paraclinical tests. The classification 
makes use of information that is obtained routinely for all patients via 
history, physical examination, and an ordinary complete blood count. 
The arterial puncture required to measure pCb is not necessarily a 
routine test, but is almost always obtained today whenever a patient 
shows any significant respiratory impairment. In the absence of any 
clinical manifestations of such impairment, p02 can safely be assumed 
to exceed the boundary value of 50 mm Hg. 
The most obvious and compelling application for the new staging 
system will be to improve the evaluation of new drugs for AIDS. In 
view of the grave prognosis of AIDS, placebo controlled trials are no 
longer considered ethical. All patients will probably receive some form 
of presumably active treatment. When compared with a previous 
treatment or with no treatment, the results of a new treatment may be 
highly deceptive or distorted if the patients are not suitably classified 
for prognostic expectations. An effective treatment may show poor 
results if given mainly to patients in Stage III; an ineffectual treatment 
may show apparently good results if given mainly to patients in Stage I. 
This type of inadvertent deception may be occurring today when the 
results of AZT are evaluated without proper prognostic staging. 
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Because of the pre-therapeutic criteria that make patients "eligible" for 
AZT treatment, the patients who receive it will usually be "healthier" 
(i.e in Stage I) than those who do not. Unless AZT (or any other 
active treatment) has many lethal side effects, the post-therapeutic 
survival results in the Stage I treated group will inevitably be superior 
when compared with results of the untreated patients in Stages II and 
III. 
When other new active treatments arise to be compared against 
AZT in randomized trials, a suitable prognostic staging system can 
enhance the efficiency with which the trials are designed, and the 
precision with which the results are analyzed.^ 
A different compelling reason for developing accurate prognostic 
staging, is the doctor’s role in the lives of the patients who suffer from 
this tragic disease. This study was originally conceived during a 
medical student’s rotation on the Fitkin Service of YNHH. As she 
cared for her newly diagnosed AIDS patient, a young woman about the 
student’s age with two children, the student was struck by what little 
useful information the medical community had to offer the patient. 
Although it was clear that the patient would die of this disease, no one 
knew if death would come in 2 months or 2 years. It was clear to the 
student in talking with her patient and her patient’s family that such 
knowledge would help them face the disease and plan how best to 
make the most of the life that remained. Such plans would include 
arrangements for the patient’s children as well as decisions about when 
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the patient’s comfort would be more important than attempts to 
eradicate whatever opportunistic infection was currently compromising 
her health. 
It is the hope of that medical student that this research project 
might in some way facilitate the future development of new effective 
therapies and in the meantime encourage frank discussions of 
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DEVELOPMENTAL SET: DEMOGRAPHICS 
Number (and %) Surviving at Cited Period 
Characteristic N (%)* 4 Mo. 
Race: 
White 27 (36%) 19 (70%) 
Black 34 (45%) 22 (65%) 
Hispanic 15 (20%) 6 (40%) 
Gender: 
Male 56 (74%) 34 (61%) 
Female 20 (26%) 13 (65%) 
Risk Factors1: 
IVDA: 
No 38 (50%) 23 (61%) 
Yes 38 (50%) 24 (63%) 
Homosexual Male: 
No 43 (57%) 29 (67%) 
Yes 33 (43%) 18 (55%) 
Heterosexual 
Exposure: 
No 63 (83%) 38 (60%) 
Yes 13 (17%) 9 (69%) 
Transfusion 
Exposure: 
No 71 (93%) 42 (59%) 
Yes 5 ( 7%) 5 (100%) 
TOTAL 76 (100%) 47 (62%) 
6 Mo. 8 Mo. 10 Mo. 12 Mo. 
14 (52%) 11 (41%) 8 (30%) 8 (30%) 
16 (47%) 11 (32%) 10 (29%) 9 (26%) 
5 (33%) 3 (20%) 3 (20%) 2 (13%) 
26 (46%) 18 (32%) 15 (27%) 14 (25%) 
9 (45%) 7 (35%) 6 (30%) 5 (25%) 
18 (47%) 13 (34%) 10 (26%) 10 (26%) 
17 (45%) 12 (32%) 11 (29%) 9 (24%) 
21 (49%) 15 (35%) 14 (33%) 13 (30%) 
14 (42%) 10 (30%) 7 (21%) 6 (18%) 
27 (43%) 19 (30%) 15 (24%) 13 (21%) 
8 (62%) 6 (46%) 6 (46%) 6 (46%) 







' 17 (24%) 15 (21%) 
4 (80%) 4 (80%) 4 (80%) 4 (80%) 
35 (46%) 25 (33%) 21 (28%) 19 (25%) 
NOTES: 
• Percent of total. 




DEVELOPMENTAL SET: AIDS DIAGNOSTIC COMPONENTS 
Baseline Disease 
In Establishing Number (and %) Surviving at Cited Period 
Diagnosis1 N (%)* 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
PCP Pneumonia: 
No 25 (33%) 15 (60%) 9 (36%) 5 (20%) 5 (20%) 5 (20%) 
Yes 51 (67%) 32 (63%) 26 (51%) 20 (39%) 16 (31%) 14 (27%) 
MAI: 
Yes 70 (92%) 45 (64%) 34 (49%) 25 (36%) 21 (30%) 19 (27%) 
No 6 ( 8%) 2 (33%) 1 (17%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Kaposi's Sarcoma: 
No 67 (88%) 42 (63%) 32 (48%) 23 (34%) 19 (28%) 17 (25%) 
Yes 9 (12%) 5 (56%) 3 (33%) 2 (22%) 2 (22%) 2 (22%) 
Crytococcus 
Infection: 
No 71 (93%) 45 (63%) 33 (47%) 24 (34%) 20 (28%) 18 (25%) 
Yes 5 ( 7%) 2 (40%) 2 (40%) 1 (20%) 1 (20%) 1 (20%) 
Toxoplasmosis: 
No 73 (96%) 45 (62%) 34 (47%) 24 (33%) 21 (29%) 19 (26%) 
Yes 3 ( 4%) 2 (66%) 1 (33%) 1 (33%) 0 ( 0%) 0 ( 0%) 
Brain Cancer: 
No 75 (99%) 46 (61%) 34 (45%) 25 (33%) 21 (28%) 19 (25%) 
Yes 1 ( 1%) 1 (100%) 1 (100%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Candida Esophagitis: 
No 71 (93%) 42 (59%) 32 (45%) 22 (31%) 19 (27%) 17 (24%) 
Yes 5 ( 7%) 5 (100%) 3 (60%) 3 (60%) 2 (40%)) 2 (40%) 
Other Dx2: 
No 68 (89%) 43 (63%) 33 (49%) 24 (35%) 21 (31%) 19 (28%) 
Yes 8 (11%) 4 (50%) 2 (25%) 1 (13%) 0 ( 0%) 0 ( 0%) 
TOTAL 76 47 (62%) 35 (46%) 25 (33%) 21 (28%) 
19 (25%) 
NOTES: 
• Percent of total. 
1 Patient could have >1 of these characteristics. 
2 Other included: CMV, cryptosporidiosis, disseminated herpes zoster, disseminated 
camphlobacter , progressive multifocal leukoencephalopathy, 




DEVELOPMENTAL SET: HISTORY (SYMPTOMS) 
Number (and %) Surviving at Cited Period 













































































































































TOTAL 76 (100%) 47 (62%) 35 (46%) 25 (33%) 21 (28%) 19 (25%) 
[This table is continued on the next page] 
NOTES: 
• Percent of total. 
l Patient could have >1 of these characteristics. 
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TABLE 3 (Continued) 
DEVELOPMENTAL SET: HISTORY (SYMPTOMS) 
Characteristic N (%)* 
Number (and %) Surviving at Cited Period 
4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
Cough & Chest Pain1: 
None 20 (26%) 15 (75%) 11 (55%) 5 (25%) 4 (20%) 4 (20%) 
Cough 55 (72%) 31 (56%) 23 (42%) 19 (35%) 16 (29%) 14 (25%) 
Non-Pleuritic CP 2 ( 3%) 2 (100%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Pleuritic 20 (26%) 10 (50%) 10 (50%) 9 (45%) 8 (40%) 8 (40%) 
Dyspnea: 
None 30 (39%) 19 (63%) 13 (43%) 7 (23%) 6 (20%) 5 (17%) 
On Exertion 38 (50%) 23 (61%) 18 (47%) 15 (39%) 14 (37%) 13 (34%) 
At Rest 8 (11%) 5 (63%) 4 (50%) 3 (38%) 1 (13%) 1 (13%) 
Eye Sx: 
None 72 (95%) 45 (63%) 33 (46%) 25 (35%) 21 (29%) 19 (26%) 
Visual Blur A ( 5%) 2 (50%) 2 (50%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Encephalomeningeal 
Sx:1 
None 61 (80%) 43 (70%) 33 (54%) 24 (39%) 20 (33%) 18 (30%) 
Stiff Neck 5 ( 7%) 1 (20%) 1 (20%) 1 (20%) 1 (20%) 1 (20%) 
Seizures 5 ( 7%) 2 (40%) 2 (40%) 1 (20%) 1 (20%) 1 (20%) 
Lethargy/Confusion 12 (16%) 4 (33%) 2 (17%) 1 ( 8%) 1 ( 8%) 1 ( 8%) 
Photophobia 3 ( 4%) 1 (33%) 1 (33%) 1 (33%) 1 (33%) 1 ( 8%) 
Any 15 (20%) 4 (27%) 2 (13%) 1 ( 7%) 1 ( 7%) 1 ( 7%) 
Other 
Neurological Sx:1 
None 68 (89%) 41 (60%) 33 (49%) 25 (37%) 21 (31%) 19 (28%) 
Dysarthria/Aphasia A ( 5%) 2 (50%) 1 (25%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Paralysis 6 ( 8%) 4 (67%) 2 (33%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Dementia 3 ( 4%) 2 (67%)) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Any 8 (11%) 6 (75%) 2 (15%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
TOTAL 76 (100%) 47 (62%) 35 (46%) 25 (33%) 21 (28%) 
19 (25%) 
NOTES: 
• Percent of total. 




DEVELOPMENTAL GROUP: COMORBIDITY DATA 
Number (and %) Surviving at Cited Period 
Characteristic N (%)* 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
History of Related 
Diagnosis1: 
None 38 (50%) 22 (59%) 17 (45%) 13 (34%) 11 (29%) 11 (29%) 
Hepatitis B 28 (37%) 18 (64%) 11 (39%) 10 (36%) 6 (21%) 6 (21%) 
CMV 2 ( 3%) 1 (50%) 1 (50%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Syphillia 3 ( 4%) 3 (100%) 2 (67%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Gonorrhea 11 (14%) 8 (73%) 6 (55%) 4 (36%) 4 (36%) 4 (36%) 
Endocarditis 6 ( 8%) 2 (33%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Alcohol Abuse: 
None or Social 54 (71%) 32 (59%) 26 (48%) 18 (33%) 14 (26%) 12 (22%) 
"Noted" 20 (26%) 14 (70%) 8 (40%) 6 (30%) 6 (30%) 6 (30%) 
"Evidence Sd Eff" 2 ( 3%) 1 (50%) 1 (50%) 1 (50%) 1 (50%) 1 (50%) 
Cigarette Smoking: 
None 30 (39%) 18 (60%) 12 (40%) 8 (27%) 6 (20%) 5 (17%) 
£ 1 ppd x10 yrs 23 (30%) 14 (61%) 10 (43%) 7 (30%) 6 (26%) 5 (22%) 




64 (84%) 40 (63%) 31 (48%) 22 (34%) 19 (30%) 17 (27%) 
Related to IVDA 1 ( 1%) 1 (100%) 1 (100%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
"Psychotic" 2 ( 3%) 1 (50%) 1 (50%) 1 (50%) 1 (50%) 1 (50%) 
Depression/Suicide 9 (12%) 5 (56%) 2 (22%) 2 (22%) 1 (11%) 1 (11%) 
TOTAL 76 (100%) 47 (62%) 35 (46%) 25 (33%) 21 (28%) 19 (2 5%) 
NOTES: 
• Percent of total. 




DEVELOPMENTAL SET: PHYSICAL EXAMINATION (SIGNS') 
Number (and %) Surviving at Cited Period 
Characteristic N (%)* 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
Oral Thrush 
No 23 (30%) 17 (74%) 14 (61%) 11 (48%) 10 (43%) 9 (39%) 
Yes 53 (70%) 30 (57%) 21 (40%) 14 (26%) 11 (21%) 10 (19%) 
Lymphadenopathy: 
No 24 (32%) 12 (50%) 6 (25%) 3 (13%) 3 (13%) 3 (13%) 
Detectable 47 (63%) 32 (68%) 26 (55%) 21 (45%) 17 (36%) 16 (34%) 
Pronounced 4 ( 5%) 3 (75%) 3 (75%) 1 (25%) 1 (25%) 0 ( 0%) 
Kaposi's Sarcoma: 
None 64 (84%) 40 (63%) 30 (47%) 21 (33%) 18 (28%) 17 (27%) 
<10 Lesions; or 
1 Location 1 ( 1%) 1 (100%) 1 (100%) 1 (100%) 0 ( 0%) 0 ( 0%) 
£10 Lesions; or 
2 Locations 5 ( 7%) 2 (40%) 2 (40%) 1 (20%) 1 (20%) 0 ( 0%) 
>2 Locations 6 ( 8%) 4 (67%) 2 (33%) 2 (33%) 2 (33%) 2 (33%) 
Eye Lesions: 
None 70 (92%) 45 (64%) 33 (47%) 23 (33%) 20 (29%) 18 (26%) 
Retinal Abnormality 6 ( 8%) 2 (33%) 2 (33%) 2 (33%) 1 (17%) 1 (17%) 
Encephalomeningeal 
Signs1: 
None 69 (91%) 44 (64%) 33 (48%) 24 (35%) 20 (29%) 18 (26%) 
Stiff Neck 4 ( 5%) 2 (50%) 2 (50%) 1 (25%) 1 (25%) 1 (25%) 
Seizures 1 ( 1%) 1 (100%) 1 (100%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Severe Lethargy 5 ( 7%) 2 (40%) 1 (20%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Any 7 ( 9%) 3 (43%) 2 (29%) 1 (14%) 1 (14%) 1 (14%) 
Neurological 
Signs1: 
None 69 (91%) 43 (62%) 33 (48%) 24 (35%) 20 (29%) 18 (26%) 
Dysarthria/Aphasia 4 ( 5%) 2 (50%) 1 (25%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Paralysis 6 ( 8%) 2 (33%) 2 (33%) 1 (17%) 1 (17%) 1 (17%) 
Dementia 3 ( 4%) 2 (67%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Any 7 ( 9%) 4 (57%) 2 (29%) 1 (14%) 1 (14%) 
1 (14%) 
TOTAL 76 (100%) 47 (62%) 35 (46%) 25 (33%) 21 (28%) 
19 (25%) 
NOTES: 
• Percent of total. 





DEVELOPMENTAL SET: PARACLINICAL DATA CLABORATORY DATA) 
Number (and %) Surviving at Cited Period 
Characteristic N (%)* 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
Serologies1: 
None Positive 48 (63%) 28 (53%) 21 (44%) 16 (33%) 14 (29%) 14 (29%) 
Hepatitis B 23 (30%) 17 (74%) 13 (50%) 9 (39%) 7 (30%) 5 (22%) 
CMV 5 ( 7%) 1 (20%) 1 (20%) 1 (20%) 0 ( 0%) 0 ( 0%) 
Toxoplasmosis 4 ( 5%) 3 (7 5%) 2 (50%) 1 (25%) 0 ( 0%) 0 ( 0%) 
Crytococcosis 1 ( 1%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Anergy1: 
Not Tested/Unknown 45 (59%) 28 (62%) 22 (58%) 14 (35%) 12 (30%) 10 (25%) 
Normal 3 ( 4%) 2 (67%) 2 (67%) 2 (67%) 1 (33%) 1 (33%) 
Partial 4 ( 6%) 3 (75%) 3 (75%) 2 (50%) 2 (50%) 2 (50%) 
Complete 24 (34%) 14 (58%) 8 (33%) 7 (29%) 6 (25%) 6 (25%) 
Chest Xray Findings1 
Not Done 3 ( 4%) 2 (67%) 2 (67%) 2 (67%) 2 (67%) 2 (67%) 
Normal 21 (28%) 12 (57%) 7 (33%) 4 (19%) 4 (19%) 4 (19%) 
Diffuse Infiltrate 43 (57%) 27 (63%) 21 (49%) 14 (33%) 10 (23%) 8 (19%) 
Lobular Infiltrate 14 (18%) 8 (57%) 7 (50%) 6 (43%) 6 (43%) 5 (36%) 
Cavitary Lesion 4 ( 5%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Head CT1: 
Not Done 57 (75%) 37 (65%) 29 (51%) 21 (37%) 17 (30%) 16 (28%) 
Normal 12 (16%) 7 (58%) 4 (33%) 3 (25%) 3 (25%) 3 (25%) 
Ring Enhancing 
Lesion 4 ( 5%) 1 (25%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Mass Effect 2 ( 3%) 1 (50%) 1 (50%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Other2 3 ( 4%) 2 (67%) 2 (67%) 1 (33%) 1 (33%) 0 ( 0%) 
TOTAL 76 (100%) 47 (62%) 35 (46%) 25 (33%) 21 (28%) 19 (25%) 
NOTES: 
• Percent of total. 
1 Patients could have >1 of these characteristics. 
2 Other included: right cerebellar low density lesion; hypodense area in left 
frontoparietal area; and atrophy. 

TABLE 7 
DEVELOPMENTAL SET: DIMENSIONAL VARIABLES 
Variable N# Mean 
Demographics: 
Age 76 35.1 
History IntervalsCmos): 
From first Sx to ZT 76 13.1 
Duration Syst Sx 57 3.1 
Duration Diarrhea 65 3.1 
Duration Pulm Sx 64 2.6 
Weight Loss (lbs): 
Amount 66 22.0 
Period (mos) 51 6.68 
% Wt Loss 60 5.7 
Normal State1 31 11.4 
Adm State1 32 -12.0 
Highest Fever(F ): 33 103.1 
Physical Exam: 
Temperature 65 100.5 









8.1 0.1-99.9+ .11 
0.7 0-99.9 .07 
0.1 0-99.9 .30* 
0.9 0-24 .22 
20.0 0-96 -.07 
4.1 1-25 .24 
3.0 0-25 .15 
9.0 -14-79 -.12 
-15.0 -58-49 .07 





24.0 12-56 .00 






28 63.0 32.5 0-463 -.26 
27 12.4 11.0 0-73 .05 
26 232.9 174.5 8-896 -.07 
27 43.0 40 8-82 .30 
40 0.4 0.3 0-1.0 -.19 
Complete Blood Count: 
Hematocrit 76 33.0 33.8 18.7-51.6 
. 3Z** 
WBC 75 5.2 4.8 1.5-9.9 
-.04 
Calc Lymphs 73 758.5 520.0 0-7020 
.26* 
Platelets 46 241.4 236.5 8-566 
-. 12 
Sedimentation Rate 34 52.2 54.0 17-78 
-.11 
Arterial Blood Gas 
(Rm Air) 
pH 57 744.2 744.0 
728-755 
PC02 57 31.4 32.0 
19-45 -.04 
P02 57 72.4 75.0 
28-122 . 17 
Albumin 42 2.5 2.5 
1.2-4.0 .19 
NOTES: 
• Percent of total; * = P $.05; ** = P $ .01; t = 
Maximum coding value was 99 
1 Normal State refers to normal weight & Admission State refers to admission weight 
Patients weights were subtracted from their ideal body weight (IBW, Appendix ) 
to determine if they were above (+) or below (-) IBW. 
2 Some patients only had %'s or T4/T8 ratios given rather than a full T cell count. 

TABLE 8 
DEVELOPMENTAL SET: STAGING COMPONENTS AND UNIONS 
Median 
(Survival Number Land %) Surviving at Cited Period 














1 ( 5%) 
20 (35%) 






P02 > 50 or 
Not Tested 
















































0 ( 0%) 
21 (30%) 







Not Tested 65 (86%) 








1 ( 9%) 
20 (31%) 
1 ( 9%) 
18 (28%) 
1 ( 9%) 
)penic 
;ritv : 
Tone 48 (63%) 6.9 35 (73%) 
'ytopenia1: 
1 of 3 18 (24%) 3.9 9 (50%) 
3MF2: *2 of 3 10 (13%) 2.3 3 (30%) 
lL 76 (100%) 5.5 47 (62%) 
27 (56%) 21 (44%) 17 (35%) 16 (33%) 
6 (33%) 4 (22%) 4 (22%) 3 (17%) 
2 (20%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
35 (46%) 25 (33%) 21 (28%) 19 (25%) 
rcent of total. 
topenia refers to any 1 of 3 possible cytopenias (HCT<30; WBC <2,500 
PLTS <150,000). 




DEVELOPMENTAL SET: NADIR AND ZENITH COMPONENTS AND UNIONS 
Number (and %) Surviving at Cited Period 
Hnmnonents N (%) Median 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
avitary Lesion 
n Chest X-Ray: 
No 72 (95%) 5.7 47 (65%) 35 (49%) 25 (35%) 21 (29%) 19 (26%) 
Yes 4 ( 5%) 2.1 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
ing Enhancing 
T Lesion: 
No 72 (95%) 5.7 46 (64%) 35 (49%) 25 (35%) 21 (29%) 19 (26%) 
Yes 4 ( 5%) 1.7 1 (25%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
ndocarditis: 
No 70 (92%) 5.3 45 (64%) 35 (50%) 25 (36%) 21 (30%) 19 (27%) 
Yes 6 ( 8%) 2.5 2 (33%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
[ieh Lymphs: 
< 1500 59 (81%) 6.6 34 (58%) 25 (42%) 17 (29%) 14 (24%) 12 (20%) 
£1500 14 (19%) 3.6 11 (79%) 8 (57%) 6 (43%) 5 (36%) 5 (36%) 
Hood Tranfusion: 
No 71 (93%) 5.0 42 (59%) 31 (44%) 21 (30%) 17 (24%) 15 
(21%) 




No 65 (86%) 6.4 44 (68%) 35 (54%) 25 (38%) 21 (32%) 
19 (29%) 
Yes 11 (14%) 2.4 3 (27%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
0 ( 0%) 
Zenith Group2 
No 67 (88%) 5.0 38 (57%) 28 (42%) 18 (27%) 
14 (21%) 12 (18%) 
Yes 9 (12%) 14.9 9 (100%) 7 (78%) 7 (78%) 
7 (78%) 7 (78%) 
TOTAL 76 (100%) 5.5 47 (62%) 35 (46%) 25 (33%) 
21 (28%) 19 (25%) 
NOTES: 
l Nadir Group: Cavitary lesions on CXR, or Ring Enhancing 
lesions on Head 
CT scan, or Endocarditis. 
2 Zenith Group: Lymphs £1500 or blood tranfusion risk 

TABLE 10 
DEVELOPMENTAL SET: NUTRITIONAL STATUS 
Number Cand %) Surviving at Cited Period 
Characteristic N (%)* 4 Mo. 6 i Mo. 8 Mo. 10 Mo. 12 Mo. 
Wt. Loss Hx: 
No 65 (86%) 38 (58%) 28 (43%) 20 (31%) 16 (25%) 15 (23%) 
Yes 11 (14%) 9 (82%) 7 (64%) 5 (45%) 5 (45%) 4 (36%) 
Reported Loss: 
Unk 21 (28%) 13 (62%) 9 (43%) 6 (29%) 6 (29%) 5 (24%) 
< 20 20 (26%) 16 (80%) 14 (70%) 10 (50%) 8 (40%) 7 (35%) 
220 35 (46%) 18 (51%) 12 (34%) 9 (26%) 7 (20%) 7 (20%) 
% Calculated: 
Unk 50 (68%) 31 (62%) 23 (46%) 16 (32%) 15 (30%) 14 (28%) 
$ 10% 9 (12%) 5 (56%) 4 (44%) 2 (22%) 2 (22%) 2 (22%) 
>10%- $15% 9 (12%) 6 (67%) 5 (56%) 4 (44%) 2 (22%) 1 (11%) 
>15% 8 (11%) 5 (63%) 3 (38%) 3 (38%) 2 (25%) 2 (25%) 
Normal State: 
Unk 46 (61%) 27 (59%) 19 (41%) 13 (30%) 12 (26%) 12 (26%) 
Nl/Thin 20 (26%) 14 (70%) 12 (60%) 8 (40%) 6 (30%) 5 (25%) 
Obese 10 (13%) 6 (60%) 4 (40%) 4 (40%) 3 (30%) 2 (20%) 
Adm. State: 
Unk 44 (58%) 27 (61%) 19 (43%) 13 (30%) 12 (27%) 12 (27%) 
Nl/Thin1 28 (37%) 18 (64%) 14 (50%) 10 (36%) 7 (25%) 6 (21%) 
Obese2 4 ( 5%) 2 (50%) 2 (50%) 2 (50%) 2 (50%) 1 (25%) 
Albumin: 
< 2.5 54 (71%) 31 (57%) 23 (43%) 18 (33%) 14 (26%) 14 (26%) 
2 2.5 22 (29%) 16 (73%) 12 (55%) 7 (32%) 7 (32%) 5 (23%) 
Diarrhea: 
None 37 (49%) 25 (68%) 17 (46%) 15 (41%) 13 (35%) 11 (30%) 
Intermittent 20 (27%) 14 (70%) 13 (65%) 7 (35%) 5 (25%) 5 (25%) 
Constant 18 (24%) 7 (39%) 5 (28%) 3 (17%) 3 (17%) 3 (17%) 
Diarrhea Class: 
Not Significant 71 (95%) 44 (62%) 33 (46%) 24 (34%) 20 (28%) 18 (25%) 
Significant 4 ( 5%) 2 (50%) 2 (50%) 1 (25%) 1 (25%) 1 (25%) 
Unions 
Obese, $ 10%i 6 (20%) 3 (50%) 2 (33%) 2 (33%) 2 (33%) 1 (17%) 
Obese, >10%i 4 (13%) 3 (75%) 2 (50%) 2 (50%) 1 (25%) 1 (25%) 
Nl/Thin, $10%1 7 (23%) 6 (86%) 6 (86%) 3 (43%) 3 (43%) 3 (43%) 
Nl/Thin, >10%1 13 (43%) 8 (62%) 6 (46%) 5 (38%) 3 (23%) 2 (15%) 
TOTAL 76 (100%) 47 (62%) 35 (46%) 25 (33%) 21 (28%) 19 (25%) 
NOTE: 
• Percent of total. 
l Nl/Thin was defined as $20 lbs. over actual weight as per Appendix VII[. 




DEVELOPMENTAL SET: FINAL STAGING SYSTEM 
Median Number (and %) Surviving at Cited Period 
STAGE1 N (%) (mos.) 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
I 28 (37%) 11.2 25 (89%) 21 (75%) 18 (64%) 15 (54%) 14 (50%) 
II 38 (50%) 3.9 19 (50%) 12 (32%) 7 (18%) 6 (16%) 5 (13%) 
III 10 (13%) 2.3 3 (30%) 2 (20%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
TOTAL 76 (100%) 5.5 47 (62%) 35 (46%) 25 (33%) 21 (28%) 19 (25%) 
NOTES: 
• Percent of total. 
1 The staging system had the following components and arrangements: 
COMPONENTS OF STAGING OF OVERT AIDS 
— Hypoxemia: P02-£50. 
— Neurologic Deficit: stiff neck; seizures; severe lethargy or confusion; 
photophobia; dysarthria or aphasia; partial or complete paralysis; or dementia. 
— Cytopenias: hematocrit <30; WBC <2,500; Platelets <140,000. 
STAGING ARRANGEMENTS 
STAGE X: None of the functional deficits listed above. 
STAGE II: Any one of the deficits listed above, but no more than one cytopenia. 




CHALLENGE SET: DEMOGRAPHICS 
Number (and %) Surviving at Cited Period 
Characteristic N (%)* 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
Race: 
White 24 (59%) 11 (46%) 9 (38%) 9 (38%) 4*(20%) 2*(11%) 
Black 16 (39%) 9 (56%) 7 (44%) 4*(29%) 0*( 0%) 0*( 0%) 
Hispanic 1 ( 2%) 1 (100%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Gender: 
Male 33 (80%) 15 (45%) 11 (33%) 9*(28%) 3*(12%) 1*( 4%) 
Female 8 (20%) 6 (75%) 5 (63%) 4*(57%) 1*(20%) 1*(20%) 
Risk Group1: 
IVDA: 
No 23 (56%) 13 (57%) 10 (43%) 10 (43%) 2*(13%) 1*( 7%) 
Yes 18 (44%) 8 (44%) 6 (33%) 3*(19%) 2*(13%) 1*( 7%) 
Homosexual Male: 
No 21 (51%) 13 (62%) 10 (48%) 7*(37%) 3*(19%) 1*( 7%) 
Yes 20 (49%) 8 (40%) 6 (30%) 6 (30%) 1*( 7%) 1*( 7%) 
Heterosexual 
Exposure: 
No 36 (88%) 17 (47%) 13 (36%) 10*(29%) 4*(14%) 2* ( 7%) 
Yes 5 (12%) 4 (80%) 3 (60%) 3 (60%) 0*( 0%) 0*( 0%) 
Transfusion 
Exposure: 
No 39 (95%) 20 (51%) 15 (38%) 12*(32%) 4*(14%) 2*( 7%) 
Yes 2 ( 5%) 1 (50%) 1 (50%) 1 (50%) 0 ( 0%) 0 ( 0%) 
TOTAL 41 (100%) 21 (51%) 16 (39%) 13*(33%) 4*(13%) 2*( 7%) 
NOTES: 
• Percent of total. 
l Patient could have >1 of these characteristics. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 




CHALLENGE SET: AIDS DIAGNOSIS 
Baseline Disease _Number (and %) Surviving at Cited Period 
Establishing Dx1 N (%)* 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
PCP Pneumonia: 
No 16 (39%) 8 (50%) 6 (38%) 5 (31%) 1*( 8%) 1*( 8%) 
Yes 25 (61%) 13 (52%) 10 (40%) 8*(35%) 3*(17%) 1*( 6%) 
MAI: 
Yes 37 (90%) 20 (54%) 16 (43%) 13*(37%) 4*(15%) 2* ( 8%) 
No 4 (10%) 1 (25%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Kaposi's Sarcoma: 
No 37 (90%) 19 (51%) 14 (38%) 11*(31%) 4*(14%) 2*( 7%) 
Yes 4 (10%) 2 (50%) 2 (50%) 2 (50%) 0*( 0%) 0*( 0%) 
Crytococcus: 
Infection: 
No 36 (88%) 17 (47%) 12 (33%) 10*(29%) 3*(11%) 1*( 4%) 
Yes 5 (12%) 4 (80%) 4 (80%) 3 (60%) 1*(33%) 1*(33%) 
Toxoplasmosis: 
No 36 (88%) 20 (56%) 15 (42%) 13*(37%) 4*(15%) 2*( 8%) 




41 (100%) 21 (51%) 16 (39%) 13*(33%) 4*(13%) 2*( 7%) 
Candida Esophagitis: 
No 37 (90%) 19 (51%) 15 (41%) 12*(34%) 4*(15%) 2*( 8%) 
Yes 4 (100%) 2 (50%) 1 (25%) 1 (25%) 0 ( 0%) 0 ( 0%) 
Other Dx2: 
No 40 (98%) 20 (50%) 16 (40%) 13*(34%) 4*(13%) 2*( 7%) 
Yes 1 ( 2%) 1 (100%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
TOTAL 41 (100%) 21 (50%) 16 (39%) 13 (33%) 4 (13%) 2 ( 7%) 
NOTES: 
• Percent of total. 
1 Patient could have >1 of these characteristics. 
2 Other included: See Table 2 and text. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 
denominator of people followed for at least as long as the cited period of time. 
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TABLE 14 
CHALLENGE SET: FINAL STAGING SYSTEM 
Median 
(mos.) 
Number (and %) Surviving at Cited Period 
STAGE1 N (%)* 4 Mo. 6 Mo. 8 Mo! 10 Mot^ 12 Mot^* 
I 15 (37%) 7.2 11 (73%) 9 (60%) 8 (53%) 2*(20%) 1*(11%) 
II2 19 (46%) 1.6 8 (42%) 5 (26%) 4*(22%) 2*(13%) 1*( 7%) 
III3 7 (17%) 0.7 2 (29%) 2 (29%) 1*(17%) 0*( 0%) 0*( 0%) 






1 For description of the stages, see Table 11 and text. 
• Percent of total. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 
denominator of people followed for at least as long as the cited period of time. 
Median values in bold print (Stage I) are conservative estimates that assume 
patients died on date of their last follow-up while alive. 
t At 8 months, a total of 2 patients are censored: 1 in Stage II; 1 in Stage 
III. 
ft At 10 months, a total of 10 patients are censored: 5 in Stage I; 3 in 
Stage II; and 2 in Stage III. 
ftt At 12 months a total of 12 patients censored: 6 in Stage I; 4 in Stage II 




CHALLENGE SET: NADIR AND ZENITH COMPONENTS AND UNIONS 
Number (and %) Surviving at Cited Period 
imponents N (%)* Median 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
avitary Lesion 
a Chest X-Ray: 
No 40 (98%) 4.2 20 (50%) 15 (38%) 12*(32%) 3*(10%) 2 ( 7%) 
Yes 1 ( 2%) 10.2 1 (100%) 1 (100%) 1 (100%) 1 (100%) — 
ing Enhancing 
T Lesion: 
No 36 (88%) 4.4 19 (53%) 14 (39%) 12*(34%) 3*(11%) 1*( 4%) 
Yes 5 (12%) 3.1 2 (40%) 2 (40%) 1*(25%) 1*(25%) 1*(25%) 
idocarditis: 
No 37 (90%) 3.2 17 (46%) 13 (35%) 12*(33%) 3*(11%) 1*( 4%) 
Yes 4 (10%) 7.1 4 (100%) 3 (75%) 1*(33%) 1*(33%)) 1*(33%) 
igh Lymphs: 
< 1500 30 (75%) 4.6 15 (50%) 10 (33%) 8*(29%) 3*(13%) 1*( 5%) 
£1500 10 (25%) 4.3 5 (50%) 5 (50%) 5 (50%) 1*(14%) 1*(14%) 
lood Tranfusion: 
No 39 (95%) 4.3 20 (51%) 15 (38%) 12*(32%) 4*(14%) 2*( 7%) 
Yes 2 ( 5%) 5.0 1 (50%) 1 (50%) 1 (50%) 0 ( 0%) 0 ( 0%) 
aions 
adir Group1: 
No 31 (76%) 3.2 14 (45%) 10 (32%) 10 (32%) 1*( 4%) 0*( 0%) 
Yes 10 (24%) 6.1 7 (70%) 6 (60%) 3*(38%) 3*(38%) 2*(29%) 
enith Group2 
No 35 (54%) 4.0 17 (49%) 12 (34%) 9*(27%) 3*(11%) 1*( 4%) 
Yes 6 (15%) 8.8 4 (67%) 4 (67%) 4 (67%) 1*(25%) 1*(25%) 
DIAL 41 (100%) 4.2 21 (51%) 16 (39%) 13*(33%) 4*(13%) 2*( 7%) 
3TES: 
Nadir Group: Cavitary lesions on CXR, or Ring Enhancing lesions on Head CT 
scan, or Endocarditis. 
Zenith Group: Lymphs £1500 or blood tranfusion risk 
Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 





CHALLENGE SET; STAGING COMPONENTS AND UNIONS 
Number (and %) Surviving at Cited Period 
nmponents N (%)* Median 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
eurologic 
anifestations: 
No 29 (71%) 5.0 17 (59%) 12 (41%) 10*(36%) 3*(14%) 1*( 5%) 
Yes 12 (29%) 2.1 4 (37%) 4 (33%) 3*(27%) 1*(11%) 1*(11%) 
VDOxia: 
P02 > 50 38 (93%) 4.8 21 (55%) 16 (42%) 13*(36%) 4*(14%) 2*(08%) 
P02 £ 50 3 (07%) 0.1 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
ytopenias: 
ematocrit: 
* 30 29 (71%) 4.5 16 (55%) 13 (45%) 11*(39%) 3*(14%) 2*(10%) 
<30 12 (29%) 2.2 5 (42%) 3 (2 5%) 2*(18%) 1*(10%) 0*( 0%) 
BC; 
£ 2,500 36 (88%) 4.4 19 (53%) 15 (42%) 13*(37%) 4*(15%) 2*( 8%) 
< 2,500 5 (12%) 2.7 2 (40%) 1 (20%) 0*( 0%) 0*( 0%) 0*( 0%) 
latelets: 
>✓140,000 30 (73%) 5.1 18 (60%) 13 (43%) 11*(38%) 4*(17%) 2*(10%) 
<140,000 11 (27%) 0.7 3 (27%) 3 (27%) 2*(20%) 0*( 0%) 0*( 0%) 
ytopenic 
everitv: 
None 21 (51%) 6.1 13 (62%) 11 (52%) 10 (40%) 3*(20%) 2*(14%) 
Cytopenia1 
1 of 3 13 (32%) 1.6 6 (40%) 3 (23%) 2*(17%) 1*( 9%) 0*( 0%) 
BMF2: )2 Of 3 7 (17%) 0.7 2 (29%) 2 (29%) 1*(17%) 0*( 0%) 0*( 0%) 
OTAL 41 (100%) 4.2 21 (51%) 16 (39%) 13*(33%) 4*(13%) 2*( 7%) 
OTE: 
• Percent of total. 
l Cytopenia refers to any 1 of 3 possible cytopenias (HCT<30; WBC < 2,500; or PLTS 
<150,000). 
2 BMF (bone marrow failure) refers to the presence of £2 cytopenias. 
Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 





TOTAL SET: DEMOGRAPHIC DATA 
Numb 
Characteristic N (%)* 4 Mo. 
Race: 
White 51 (44%) 30 (59%) 
Black 50 (43%) 31 (62%) 
Hispanic 16 (14%) 7 (44%) 
Gender: 
Male 89 (76%) 49 (55%) 
Female 28 (24%) 19 (68%) 
Risk Group1: 
IVDA: 
No 61 (52%) 36 (59%) 
Yes 56 (48%) 32 (57%) 
Homosexual Male: 
No 64 (55%) 42 (66%) 
Yes 53 (45%) 26 (49%) 
Heterosexual 
Exposure: 
No 99 (85%) 55 (56%) 
Yes 18 (15%) 13 (72%) 
Transfusion 
Exposure: 
No 110 (94%) 62 (56%) 
Yes 7 ( 6%) 6 (86%) 
TOTAL 117 (100%) 68 (58%) 
NOTES: 
• Percent of total. 
1 Patients could have >1 of these charact 
\r (and %) Surviving at Cited Period 





















































51 (44%) 38*(33%) 25*(23%) 21*(20%) 
eristics. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 




TOTAL SET: AIDS DIAGNOSTIC COMPONENTS 
Number (and %) Surviving at Cited Period 
Baseline Disease1 N (%1* 4 Mo. 6 i Mo. 8 Mo. 10 Mo. 12 Mo. 
Establishing Dx: 
PCP Pneumonia: 
No 41 (35%) 23 (56%) 15 (37%) 10 (24%) 6*(16%) 6*(16%) 
Yes 76 (65%) 45 (59%) 36 (47%) 28*(37%) 19*(28%) 15*(22%) 
MAI: 
Yes 107 (91%) 65 (61%) 50 (47%)) 38*(36%) 25*(26%) 21*(22%) 
No 10 ( 9%) 3 (30%) 1 (10%) 0*( 0%) 0*( 0%) 0*( 0%) 
Kaposi's Sarcoma: 
No 104 (89%) 61 (59%) 46 (44%) 34*(33%) 23*(24%) 19*(20%) 
Yes 13 (11%) 7 (54%) 5 (38%) 4 (31%) 2*(18%) 2*(18%) 
Crytococcus 
Infection: 
No 107 (91%) 62 (58%) 45 (42%) 34*(32%) 23*(23%) 19*(20%) 
Yes 10 ( 9%) 6 (60%) 6 (60%) 4 (40%) 2*(25%) 2*(25%) 
Toxoplasmosis: 
No 109 (93%) 65 (60%) 49 (45%) 37*(34%) 25*(25%) 21*(21%) 
Yes 8 ( 7%) 3 (38%) 2 (25%) 1*(14%) 0*( 0%) 0*( 0%) 
Brain Cancer: 
No 116 (99%) 67 (58%) 50 (43%) 38*(33%) 25*(24%) 21*(20%) 
Yes 1 ( 1%) 1 (100%) 1 (100%) 0*( 0%) 0 ( 0%) 0 ( 0%) 
Candida Esophagitis 
No 108 (92%) 61 (56%) 47 (44%) 34*(32%) 23*(23%) 19*(20%) 
Yes 9 ( 8%) 7 (78%) 4 (44%) 4 (44%) 2 (22%) 2 (22%) 
Other Dx2: 
No 108 (92%) 63 (58%) 49 (45%) 37*(35%) 25*(26%) 21*(22%) 
Yes 9 ( 8%) 5 (56%) 2 (22%) 1 (11%) 0*( 0%) 0*( 0%) 
TOTAL 117 (100%) 68 (58%) 51 (44%) 38*(33%) 25*(23%) 21*(20%) 
NOTES: 
• Percent of total. 
1 Patient could have >1 of these characteristics. 
2 Other included: See Table 2 and text. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 
denominator of people followed for at least as long as the cited period of time. 

TABLE 19 
TOTAL SET: HISTORICAL DATA (SYMPTOMS) 
Number (and %) Surviving at Cited Period 








































































































































































0 ( 0%) 
8*(33%) 
TOTAL 117 (100%) 68 (53%) 51 (44%) 38*(33%) 25*(23%) 21*(20%) 
[This table is continued on the next page] 
NOTES: 
• Percent of total. 
i Patient could have >1 than one of these. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 
denominator of people followed for at least as long as the cited period of time. 
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TABLE 19 (Continued) 
TOTAL SET; HISTORICAL DATA (SYMPTOMS) 
Number (and %) Surviving at Cited Period 
Characteristic N (%)* 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
Dyspnea: 
None 50 (43%) 30 (60%) 22 (44%) 14*(29%) 9*(20%) 7*(16%) 
On Exertion 56 (48%) 33 (59%) 25 (45%) 21*(38%) 15*(29%) 13 (26%) 
At Rest 11 ( 9%) 5 (45%) 4 (36%) 3 (27%) 1 ( 9%) 1 ( 9%) 
Eye Sx1: 
None 110 (94%) 65 (59%) 48 (44%) 37*(34%) 25*(26%) 21*(22%) 
Visual Blur 7 ( 6%) 3 (43%) 3 (43%) 1 (14%) 0*( 0%) 0*( 0%) 
Encephalomeningeal Sx1: 
None 94 (80%) 60 (64%) 45 (48%) 34*(37%) 23*(26%) 19*(22%) 
Stiff Neck 6 ( 5%) 2 (33%) 2 (33%) 2 (33%) 1*(20%) 1*(20%) 
Seizures 5 ( 4%) 2 (40%) 2 (40%) 1 (20%) 1 (20%) 1 (20%) 
Severe Lethargy 19 (16%) 7 (37%) 5 (26%) 3*(17%) 2*(12%) 1*( 6%) 
Photophobia 5 ( 4%)) 33 (60%) 3 (60%) 3 (60%) 2*(50%) 2*(50%) 
Any 23 (30%) 8 (35%) 6 (26%) 4*(18%) 2*(10%) 2*(10%) 
Other Neurological Sx1: 
None 100 (85%) 61 (61%) 48 (48%) 38*(38%) 25*(27%) 21*(24%) 
Dysarthria/AphasL a 6 ( 5%) 2 (33%) 1 (17%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Paralysis 10 ( 9%) 5 (50%) 3 (30%) 0*( 0%) 0*( 0%) 0*( 0%) 
Dementia 9 ( 3%) 3 (33%) 1 (11%) 0*( 0%) 0*( 0%) 0*( 0%) 
Any 17 (15%) 7 (41%) 3 (18%) 0*( 0%) 0*( 0%) 0*( 0%) 
TOTAL 117 (100%) 68 (58%) 51 (44%) 38*(33%) 25*(23%) 21*(20%) 
NOTES: 
• Percent of total. 
1 Patient could have > 1 than one of these. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 




TOTAL SET; COMORBIDITY DATA 
Number (and %) Surviving at Cited Period 
Characteristic N (%)* t Mo. 6 > Mo. 8 Mo. 10 Mo. 12 Mo. 
History of Related 
Diagnosis1: 
None 60 (527.) 31 (527.) 24 (407.) 20 (337.) 12*(22%) 11*(20%) 
Hepatitis B 34 (297.) 20 (597.) 15 (44%) 10*(30%) 8*(24%) 6*(18%) 
CMV 1 ( 1%) 1 (1007.) 1 (1007.) 1 (1007.) — — 
Syphillia 10 ( 97.) 6 (607.) 5 (507.) 3 (307.) 2* (227.) 2*(22%) 
Gonorrhea 15 (137.) 9 (607.) 7 (477.) 5 (337.) 4* (297.) 4*(33%) 
Endocarditis 10 ( 97.) 6 (607.) 3 (307.) 1*(11%) 1*(11%) 1*(11%) 
Alchohol Abuse: 
None or Social 84 (747.) 48 (577.) 37 (447.) 28 (337.) 17*(22%) 14*(18%) 
"Noted" 25 (227.) 17 (687.) 11 (44%) 7*(30%) 6*(26%) 6*(26%) 
"Evidence Sd Eff" 5 ( 47.) 2 (407.) 2 (407.) 2 (407.) 1*(25%) 1*(25%) 
Cigarette Smoking: 
None 47 (427.) 27 (577.) 19 (407.) 14 (307.) 9*(20%) 7*(16%) 
$ 1 ppd * 10 yrs 38 (55%) 21 (557.) 15 (397.) 11*(30%) 6*(187.0 5*(15%) 




95 (837.) 54 (577.) 42 (447.) 31*(33%) 21* (247.) 18*(21%) 
Related to IVDA 1 ( 1%) 1 (1007.) 1 (1007.) 0 ( 07.) 0 ( 07.) 0 ( 07.) 
"Psychotic" 3 ( 37.) 1 (337.) 1 (337.) 1 (337.) 1 (337.) 1 (337.) 
Depression/Suicide 16 (147.) 10 (637.) 6 (38%) 5*(33%) 2* (147.) 2* (147.) 
TOTAL 117 (1007.) 68 (587.) 51 (447.) 38*(33%) 25*(23%) 21*(207.) 
NOTES: 
• Percent of total. 
1 Patient could have >1 than one of these. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 




TOTAL SET: PHYSICAL EXAMINATION (SIGNS') 
Number (and %) Surviving at Cited Period 
Characteristic N (%)* A ► Mo. e i Mo. 8 Mo. 10 Mo. 12 Mo. 
Oral Thrush 
No 38 (32%) 27 (71%) 23 (61%) 19 (50%) 14*(41%) 11*(34%) 
Yes 79 (68%) 41 (52%) 28 (35%) 19*(25%) 11*(15%) 10*(14%) 
Lymphadenopathy: 
No 44 (38%) 21 (48%) 13 (30%) 9 (20%) 6*(14%) 5*(12%) 
Detectable 69 (59%) 44 (64%) 35 (51%) 28*(42%) 18*(30%) 16*(27%) 
Pronounced 4 ( 3%) 3 (75%) 3 (75%) 1 (25%) 1 (25%) 0 ( 0%) 
Kaposi's Sarcoma: 
None 102 (87%) 60 (59%) 45 (44%) 33*(33%) 22*(24%) 19*(21%) 
$ 10 Lesions; or 
1 Location 3 ( 3%) 2 (67%) 2 (67%) 2 (67%) 0*( 0%) 0*( 0%) 
>10 Lesions; or 
2 Locations 5 ( 4%) 2 (40%) 2 (40%) 1 (20%) 1 (20%) 0 ( 0%) 
>2 Locations 7 ( 6%) 4 (57%) 2 (29%) 2 (29%) 2 (29%) 2 (29%) 
Eye Lesions: 
None 105 (91%) 61 (58%) 46 (44%) 34*(34%) 24*(25%) 21*(22%) 
Retinal Abnormality 10 ( 9%) 4 (40%) 3 (30%) 2*(22%) 1*(11%) 1*(11%) 
Other 1 ( 1%) 1 (100%) 1 (100%) 1 (100%) 1 (100%) 0 ( 0%) 
Encephalomeningeal 
Signs:1 
None 103 (88%) 62 (60%) 46 (45%) 35*(34%) 23*(24%) 19*(20%) 
Stiff Neck 6 ( 5%) 3 (50%) 3 (50%) 2 (33%) 1*(20%) 1*(20%) 
Seizures 1 ( 1%) 1 (100%) 1 (100%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Severe Lethargy 11 ( 9%) 4 (36%) 3 (27%) 1*(10%) 1*(10%) 1*(10%) 
Photophobia 2 ( 2%) 2 (100%) 2 (100%) 2 (100%) 1*(100%)) 1*(100%) 
Any 14 (12%) 6 (43%) 5 (36%) 3*(23%) 2*(18%) 2*(18%) 
Neurological 
Signs:1 
None 101 (86%) 62 (61%) 47 (47%) 36*(36%) 24*(26%) 20*(22%) 
Dysarthria/ 
Aphasia 4 ( 3%) 2 (50%) 1 (25%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Paralysis 9 ( 8%) 4 (44%) 3 (33%) 1*(13%) 1*(13%) 1*(13%) 
Dementia 10 ( 9%) 3 (30%) 1 (10%) 0*( 0%) 0*( 0%) 0*( 0%) 
Any 16 (14%) 6 (38%) 4 (25%) 2*(13%) 1*( 6%) 1*( 6%) 
TOTAL 117 (100%) 68 (58%) 51 (44%) 38*(33%) 25*(23%) 21*(20%) 
NOTES: 
• Percent of total. 
i Patient could have >1 than one of these. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 
denominator of people followed for at least as long as the cited period of time. 

TABLE 22 
TOTAL SET: PARACLINICAL DATA (LABORATORY DATA) 
Number (and %) Surviving at Cited Period 
Characteristic N (%)* 4 • Mo. 6 i Mo. 8 Mo. 10 Mo. 12 Mo. 
Serologies1: 
None Positive 69 (59%) 37 (54%) 28 (41%) 23 (33%) 16*(25%) 15*(23%) 
Hepatitis B 36 (31%) 23 (64%) 16 (44%) 10*(29%) 7*(21%) 5*(15%) 
CMV 9 ( 8%) 4 (44%) 3 (33%) 3 (33%) 0*( 0%) 0*( 0%) 
Toxoplasmosis 5 ( 4%) 4 (80%) 3 (60%) 1*(25%) 0*( 0%) 0*( 0%) 
Cryotococcosis 5 ( 4%) 4 (80%) 4 (80%) 3 (60%) 1*(33%) 1*(33%) 
Anergy1: 
Not Tested/Unknown 83 (71%) 47 (57%) 36 (43%) 25*(33%) 16*(23%) 12*(18%) 
Normal 4 ( 4%) 3 (75%) 3 (75%) 3 (75%) 1*(33%) 1*(33%) 
Partial 4 ( 4%) 3 (75%) 3 (75%) 2 (50%) 2 (50%) 2 (50%) 
Complete 26 (23%) 15 (58%) 9 (35%) 8 (31%) 6*(24%) 6*(24%) 
Platelets: 
Not Done 9 ( 8%) 6 (67%) 5 (56%) 3 (33%) 2 (22%) 2 (22%) 
Adeno 73 (62%) 47 (64%) 38 (52%) 30*(42%) 21*(32%) 18*(28%) 
Decreased 22 (19%) 7 (32%) 5 (23%) 3*(14%) 1*( 5%) 1*( 5%) 
Increased 13 (11%) 8 (62%) 3 (23%) 2 (15%) 1 ( 8%) 0*( 0%) 
Chest Xray Findings1 
Not Done 12 (10%) 9 (75%) 9 (75%) 8 (67%) 5*(45%) 4*(44%) 
WNL 32 (27%) 19 (59%) 12 (38%) 8*(26%) 4*(15%) 4*(15%) 
Diffuse Infiltrate 60 (51%) 33 (55%) 24 (40%) 16*(27%) 11*(19%) 8*(14%) 
Lobular Infiltrate 18 (15%) 10 (56%) 8 (44%) 7 (39%) 6*(35%) 5*(29%) 
Cavity Lesions 5 (43%) 1 (20%) 1 (20%) 1 (20%) 1*(25%) 0*( 0%) 
Head CT1: 
Not Done 83 (71%) 52 (63%) 39 (47%) 30 (36%) 20*(26%) 17*(22%) 
Normal 18 (15%) 11 (61%) 8 (44%) 6*(35%) 3*(21%) 3*(21%) 
Ring Enhancing 
Lesion 9 ( 8%) 3 (33%) 2 (22%) 1*(13%) 1*(13%) 1*(13%) 
Mass Effect 2 ( 2%) 1 (50%) 1 (50%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 
Other2 7 ( 6%) 2 (29%) 2 (29%) 1 (14%) 1 (14%) 1 (14%) 
TOTAL 117 (100%) 68 (58%) 51 (44%) 38*(33%) 25*(23%) 21*(20%) 
NOTES: 
• Percent of total. 
l Patient could have >1 than one of these. 
2 Other included: enlarged ventricles; right cerebellar low density lesion; marked 
atrophy; shrinkage with increased ventricular size; hypodense area in left 
frontoparietal area; air fluid level in ethmoid; atrophy. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 




TOTAL SET: DIMENSIONAL VARIABLES 
Coefficient of 
Correlation with 
Variable N* Mean Median Range Survival in Mos. 
Demographics: 
Age 117 35.6 34.0 22-65 -0.05 
History Intervals(mos) 
From first Sx to ZT 112 12.3 7.3 0.1-99.9+ 0.08 
Duration Syst Sx 90 2.8 0.5 0-99.9 0.05 
Duration Diarrhea 99 3.0 0.1 0-99.9 0.25* 
Duration Pulm Sx 98 2.0 0.7 0-24 0.22* 
Weight LossClbs): 
Amount 97 19.2 15.0 0-96 -0.05 
Period (mos) 74 6.5 4.1 0.3-25 0.21 
% Wt Loss 91 5.3 3.0 0-25 0.16 
Normal State1 41 + 10.4 + 8.0 -28-+79 -0.06 
Adm State1 41 - 9.7 -13.0 -58-+60 0.05 
Highest Fever(F°): 58 102.0 103.0 100-106 -0.12 
Physical Exam: 
Temperature 114 100.7 101.0 96-106 0.02 
Respiratory Rate 96 24.8 23.0 12-80 -0.05 
Paraclinical Data: 
T Cell Studies2: 
T4 Count 31 66.3 36.0 0-463 -0.28 
T4 % 31 13.3 11.0 0-73 0.03 
T8 Count 29 237.8 180.0 8-896 -0.10 
T8 % 30 44.5 42.0 8-82 0.23 
T4/T8 45 0.3 0.3 0-1 -0.13 
Complete Blood Count: 
Hematocrit 117 33.1 33.7 15.6-51.6 0.30** 
WBC 117 5.1 4.5 1.1-9.9 -0.05 
Calc Lymphs 114 758.9 533.0 0-7,020 0.21* 
Platelets 77 219.5 210.0 8-566 0.03 
Sedimentation Rate 51 52.5 54.0 10-99 -0.21 
Arterial Blood Gas 
(Rm Air) 
pH 85 7.4 7.4 7.28-7.55 0.07 
PC02 85 30.9 32.0 19-45 0.04 
P02 85 74.2 77.0 28-123 0.14 
Albumin 71 2.6 2.6 0.7-4.4 0.25* 
NOTES: 
• Percent of total; * = P $ .05 • ** = P < } — r ^ .01; f = Maximum coding value ! was 99.9 
l Normal state refers to normal weight & admission state refers to admission weight 
Patients weights were subtracted from their ideal body weight (IBW; Appendix III) 
to determine if they were above (+) or below (-) 
2 Some patients only had %'s or T4/T8 ratios given 
IBW. 




TOTAL SET: SURVIVAL RESULTS. WITHIN STAGES. FOR PATIENTS 
WITH PROMPT OR DELAYED ZERO TIME 
N* Median 4 
Stage I: 
Prompt ZT 34 (42%) 9.2 28 (82%) 
Delayed ZT 9 (25%) 8.3 8 (89%) 
Stage II: 
Prompt ZT 37 (46%) 2.4 15 (41%) 
Delayed ZT 20 (56%) 5.0 12 (60%) 
Stage III 
Prompt ZT 10 (12%) 2.6 4 (40%) 
Delayed ZT 7 (19%) 1.9 1 (14%) 
Subtotals 
Prompt ZT 81 (69%) 5.0 47 (58%) 
Delayed ZT 36 (31%) 5.0 21 (58%) 
TOTAL 117 (100%) 5.0 68 (58%) 
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+ 4»4» 4*4.4. 
TT TTT 
51 (44%) 38 (33%) 25 (23%) 21 (20%) 
NOTES: 
• Percent of total. 
Bold printed medians are conservative estimates that assume patients die 
on date of last follow-up. 
f At 8 months of total of 2 people censored: 1 at Stage ii; l at Stage III. 
ft At 10 months a total of 10 people censored: 5 at Stage i; 3 at Stage ii; 
2 at Stage III. 
ttt At 12 months a total of 12 people censored: 6 at Stage i; 4 at Stage ii; 
2 at Stage III. 
* Some of data are "censored” because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 
denominator of people followed for at least as long as the cited period of time. 

TABLE 21 
TOTAL SET; STAGING COMPONENTS AND UNIONS 
Number (and %) Surviving at Cited Period 
rharacteristic N (%)* Median 4 Mo. 6 Mo. 8 Mo. 10 Mo. 12 Mo. 
Neurologic 
Manifestation: 
No 86 (74%) 6.2 57 (66%) 44 (51%) 34*(40%) 23*(29%) 19*(25%) 
Yes 31 (26%) 2.1 11 (35%) 7 (23%) 4*(13%) 2*( 7%) 2*( 7%) 
Hypoxia: 
P02 > 50 102 (87%) 5.3 64 (63%) 48 (47%) 36*(36%) 24*(26%) 20*(22%) 
P02 $ 50 15 (13%) 1.0 4 (27%) 3 (20%) 2 (13%) 1 ( 7%) 1 ( 7%) 
**Cytopenia: 
Hematocrit 
^ 30 83 (71%) 5.8 53 (64%) 41 (49%) 33*(40%) 21*(28%) 19*(26%) 
<30 34 (29%) 2.6 15 (44%) 10 (29%) 5*(15%) 4*(13%) 2*( 6%) 
WBC 
^2,500 106 (91%) 5.3 65 (61%) 49 (46%) 38*(36%) 25*(26%) 21*(22%) 
<2,500 11 ( 9%) 2.5 3 (27%) 2 (18%) 0*( 0%) 0*( 0%) 0*( 0%) 
Platelets 
*140,000 95 (81%) 5.5 61 (64%) 46 (48%) 35*(37%) 24*(27%) 20*(23%) 
<140,000 12 (19%) 2.0 7 (32%) 5 (23%) 3*(14%) 1*( 5%) 1*( 5%) 
Cytopenic 
Severitv: 
None 69 (59%) 6.7 40 (70%) 38 (55%) 31 (45%) 20*(32%) 18*(29%) 
Cytopenia 1 31 (26%) 3.6 15 (48%) 9 (29%) 6*(20%) 5*(17%) 3*(11%) 
1 of 3 
BMF2 *2 of 3 17 (15%) 2.1 5 (29%) 4 (24%) 1*( 6%) 0*( 0%) 0*( 0%) 
TOTAL 117 (100%) 5.0 68 (58%) 51 (44%) 38*(33%) 25*(23%) 21*(20%) 
NOTE: 
♦ Percent of total. 
1 Cytopenia refers to any 1 of 3 possible cytopenias (HCT <30; WBC <.2,500; 
or PLTS < 150,000). 
2 BMF (bone marrow failure) refers to the presence of ^2 cytopenias. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 




TOTAL SET: STAGING SYSTEM 
STAGE1 N (%)* 
Median 
(mos.) 
Number (and %) Surviving at Cited Period 
4 Mo. 6 Mo. 
t 
8 Mo.1 10 Mo.^ 12 Mo.^ 
I 43 (38%) 9.2 36 (84%) 30 (70%) 26 (60%) 17*(45%) 15*(41%) 
II 57 (49%) 3.5 27 (47%) 17 (30%) 11*(20%) 8*(15%) 6*(11%) 
III 17 (15%) 2.1 5 (29%) 4 (24%) 1*( 6%) 0*( 0%) 0*( 0%) 
TOTAL 117 (100%) 5.0 68 (58%) 51 (44%) 38 (33%)^ 
ft ftt 
25 (23%) 21 (20%) 
NOTES: 
l For description of the stages, see Table 11 and text. 
• Percent of total. 
* Some of data are "censored" because the patients have not yet had a chance to 
live this long. The percentages have been calculated for the appropriate 
denominator of people followed for at least as long as the cited period of time. 
Median values in bold print (Stage I) are conservative estimates that assume 
patients died on date of their last follow-up while alive. 
t At 8 months, a total of 2 patients are censored: 1 in Stage II; 1 in Stage III. 
tt At 10 months, a total of 10 patients are censored: 5 in Stage I; 3 in 
Stage II; and 2 in Stage III. 
ftt At 12 months a total of 12 patients censored: 6 in Stage I; 4 in Stage II 
2 in Stage III. 

TABLE 27 
TOTAL SET: ROTHENBERG VARIABLES VS. STAGING SYSTEM 
Note: Each cell of this table has three components. The first is N, the number of 
members in the cell. The second shows the percentage who have survived six months 
or more. The third number shows the median survival in months. 
Variable Stage I Stage II Stage III Total 
Sex: 
Male 31: 71%, 9.2 45: 29%, 3.5 13: 15%, 1.9 89: 42%, 5.0 
Female 12: 67%, 9.3 12: 33%, 4.0 4: 50%, 5.1 28: 50%, 6.0 
Race: 
White 17: 65%, 9.2 26: 42%, 4.6 8: 13%, 2.2 51: 45%, 5.1 
Black 19: 79%, 9.2 23: 22%, 3.5 8: 38%, 2.3 50: 46%, 5.1 
Hispanic 7: 57%, 7.8 6: 13%, 1.8 1: 0%, 0.5 16: 31%, 3.3 
Age: 
< 30 7: 100%, 13.2 16: 31%, 4.6 4: 0%, 2.0 27 44%, 5.1 
30-34 16: 63%, 8.1 13: 8%, 3.1 6: 17%, 1.8 35 34%, 4.1 
35-39 10: 50%, 6.2 11: 73%, 9.8 2: 50%, 3.6 23 61%, 6.6 
>y 40 10: 80%, 9.9 17: 18%, 2.1 5: 40%, 3.1 32 41%, 4.2 
Exposure: 
Homosexual 14: 64%, 8.8 24: 38%, 3.3 6: 0%, 1.8 44 41%, 4.7 
IVDA 17: 76%, 8.2 22: 23%, 3.7 8: 38%, 2.7 47 45%, 5.1 
Homosexual & IVDA 4: 50%, 7.1 4: 0%, 2.4 1: 0%, 2.7 9 22%, 3.2 
Other Onlyff 8: 75%, 12.2 7: 43%, 4.1 2: 50%, 4.3 17 59%, 8.3 
Presenting Diseases: 
KS Only 3: 67%, 9.2 4: 25%, 1.5 1: 0%, 5.5 8 38%, 5.3 
KS & PCP Only 0: — 2: 50%, 4.0 0: — — 2 50%, 4.0 
KS & Otherf 1: 100%, 8.3 0: t — 1: 0%, 1.9 2 50%, 5.1 
PCP Only 31: 71%, 9.2 24: 33%, 4.2 9: 33%, 1.9 64 52%, 6.3 
PCP & Otherf 1: 100%, 10.0 7: 14%, 2.4 1: 0%, 2.7 9 22%, 2.7 
1 Other Only 7: 57%, 6.1 20: 30%, 3.9 4: 25%, 2.3 31 35%, 4.2 
2 or More Otherf 0: 1 — 0: 1 — 1: 0%, 0.7 1 0%, 0.7 
TOTAL 43 (37%) 57 (49%) 17 (15%) 117 (100%) 
NOTES: 
t In Rothenberg et al., other MAI, Candida esophagitis, Crytococcus, toxoplasmosis 
brain Ca, and "Other Dx". 
ft In Rothenberg et al., Other included transfusion exposure, heterosexual exposure 
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WHO/CDC CASE DEFINITION FOR 
ACQUIRED IMMUNODEFICIENCY SYNDROME 
(AIDS) 
For surveillance purposes, a relatively precise case definition 
is required that includes the most characteristic manifestations of 
HIV1 infections. WHO recently adopted the case definition of AIDS in 
adults and children developed by the Centers for Disease Control (CDC) 
and endoresed by the participants at the Second Meeting of the WHO 
Collaborating Centres on AIDS held in Geneva 16-18 December 1985. The 
WHO/CDC definition, to be applied incountries where appropriate 
diagnostic techniques are available specifies that a case of acquired 
immunodeficiency syndrome (AIDS) is an illness characterized by: 
I. one or more of the opportunistic diseases listed below (diagnosed 
by methods considered reliable) that are at least moderately 
indicative of underlying cellular immunodeficiency: and 
II. absence of all known underlying causes of cellular 
immunodeficiency (other than HIV infection) and absence of all 
other causes of reduced resistance reported to be associated with 
at least one of those opportunistic diseases. 
Despite having the above, patients are excluded as AIDS casgs if 
they have negative results on testing for serum antibody to HIV, do 
not have a positive culture for HIV and have both a normal or high 
number of T-helper (0KT4 or LEU3) lymphocytes and a normal or high 
ratio of T-helper to T-suppressor (0KT8 or LEU2) lymphocytes. In the 
absence of test results, patients satisfying all other criteria in 
this definition are included as cases. 
This general case definition may be made more explicit by 
specifying: 
I. the particular diseases considered at least moderately indicative 
of cellular immunodeficiency, which are used as indicators of 
AIDS: and 
II. the known causes of cellular immunodeficiency or other causes of 
reduced resistance reported to be associated with particular 
diseases, which would disqualify a patient as an AIDS case. 
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I. Diseases at least moderately indicative of underlying cellular 
immunodeficiency: 
In the following list of diseases, the required diagnostic 
methods with positive results are shown in parentheses. "Microscopy" 
may include cytology. 
A. Protozoal and helminthic infections: 
1. cryptosporidiosis, intestinal, causing diarrhoea for over 1 month 
(on histology or stool microscopy): 
2. Pneumocystis carinii pneumonia (on histology, or microscopy of a 
"touch" preparation, bronchial washings, or sputum); 
3. strongyloidosis, causing pneumonia, central nervous system 
infection, or infection disseminated beyond the gastrointestinal 
tract (on histology); 
4. toxoplasmosis, causing infection in internal organs other than 
liver, spleen, or lymph nodes (on histology or microscopy of a 
"touch" preparation). 
B. Fungal infections: 
1. candidiasis, causing oesophagitis (on histology, or microscopy of 
a "wet" preparation from the oesophagus, or endoscopic or autopsy 
findings of white plaques on an erythematous mucosay base, but not 
by culture alone); 
2. cryptococcosis, causing central nervous system or other infection 
disseminated beyond lungs and lymph nodes (on culture, antigen 
detection, histology, or Indian ink preparation of CSF). 
C. Bacterial infections: 
1. Mycobacterium avium or intracellulare (M. avium complex), or M. 
kansasii, causing infection disseminated beyond lungs and lymph 
nodes (on culture). 
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D. Viral infections: 
1. cytomegalovirus causing infection in internal organs other than 
liver, spleen, or lymph nodes (on histology or cytology, but not 
by culture or serum antibody titre); 
2. herpes simplex virus, causing chronic mucocutaneous infection with 
ulcers persisting more than 1 month, or pulmonary, gastrintestinal 
tract (beyond mouth, throat, or rectum), or disseminated infection 
(but not encephalitis alone) (on culture, histology, or cytology); 
3. progressive multifocal leukoencephalopathy (presumed to be caused 
by papovavirus) (on histology). 
E. Cancer: 
1. Kaposi’s sarcoma (on histology); 
2. lymphoma limited to the brain (on histology). 
F. Other opportunistic infections with positive tests for HIV. 
In the absence of the above opportunistic diseases, any of the 
following diseases is considgjjed indicative of AIDS if the patient 
had a positive test for HIV: 
1. disseminated histoplasmosis (on culture, histology, or cytology); 
2. bronchial or pulmonary candidiasis (on microscopy or visualization 
grossly of characteristic white plaques on the bronchial mucosa, 
but not by culture alone); 
3. isosporiasis, causing chronic diarrhoea (over 1 month) (on 
histology or stool microscopy). 
G. Chronic lymphoid interstitial pneumonitis: 
In the absence of the above opportunistic diseases, a 
histologically confirmed diagnosis of chronic (persisting over 2 
months) lymphoid interstitial pneumonitis in a child (under 13 
years of |je) is indicative of AIDS unless tesi(s) for HIV are 
negative. The histological examination of lung tissue must show 
diffuse interstitial and peribronchiolar infiltration by 
lymphocytes, plasma cells with Russell bodies, plasmactoid 
lymphocytes and immunoblasts. Histological and culture evaluation 





H. Non-Hodgkin’s lymphoma with postive test for HIV: 
If the patient had a positive test for HIV, then the following 
histological types of lymphoma are indicative of AIDS regardless 
of anatomic site: 
I. small non-cleaved lymphoma (Burkitt’s tumor or Burkitt-like 
lymphoma), but not small cleaved lymphoma; 
2. immunoblastic sarcoma (or immunoblastic lymphoma) of B-cell or 
unknown immunological phenotype (not of T-cell type). Other terms 
which may be equivalent include: diffuse undifferentiated non- 
Hodgkin’s lymphoma, large cell lymphoma (cleaved or non-cleaved), 
diffuse histiocytic lymphoma, reticulum cell sarcoma, and high- 
grade lymphoma. 
Lymphomas should not be accepted as indicative of AIDS if they are 
described in any of the following ways: low grade, of T-cell type 
(immunological phenotype), small cleaved lymphoma, lymphocytic 
lymphoma (regardless of whether well or poorly differentiated), 
lymphoblastic leukaemia (acute or chronic), or Hodgkin’s disease 
(or Hodgkin’s lymphoma). 
II. Known causes of reduced resistance: 
1. Systemic corticosteroid therapy: 
Any infection diagnosed during or within 1 month after 
discontinuation of the corticosteroid therapy, unless symptoms 
specific for an infected anatomic site (e.g.,dyspnea for 
pneumonia, headache for encephalitis, diarrhoea for colitis) began 
before the corticosteroid therapy; 
or any cancer diagnosed during or within 1 month after 
discontinuation of more than 4 months of long-term corticosteroid 
therapy, unless symptoms specific for the anatomic sites of the 
cancer (as described above) began before the long-term 
corticosteroid therapy. 
2. Other immunosuppressive or cytotoxic therapy: 
Any infection diagnosed during or within 1 year after 
discontinuation of the immunosuppressive therapy, unless symptoms 
specific for an infected anatomic site (as described above) began 
before the long-term corticosteroid therapy. 
or any cancer diagnosed during or within 1 year after 
discontinuation of more than 4 months of long-term 
immunosuppressive therapy, unless symptoms specific for the 




3. Cancer of lymphoreticular or histiocytic tissue such as lymphoma 
(except for lymphoma localized to the brain). Hodgkin’s disease, 
lymphocytic leukaemia or multiple myeloma. 
Any infection or cancer, if diagnosed after or within 3 months 
before the diagnosis of the cancer of lymphoreticular or 
histiocytic tissue. 
4. Age 60 years or oder at diagnosis: 
Kaposi’s sarcome given that the patient has a positive test for 
HIV. 
5. Age under 28 days (neonatal) at diagnosis: 
Tomoplasmosis or herpes simplex virus infection as described 
above. 
6. Age under 6 months at diagnosis: 
Cytomegalovirus infection, as described above. 
7. An immunodeficiency atypical of AIDS, such as one involving 
hypogammaglobulinaemia or angioimmunoblastic lymphadenopathy; or 
an immunodeficiency of which the cause appears to be a genetic or 
developmental defect, rather thay HIV infection: 
Any infection or cancer diagnosed during such immunodeficiency. 
8. Exogenous malnutrition (starvation due to food deprivation, not 
malnutrition due to malabsorption or illness). 
Any infection or cancer diagnosed during or within 1 month after 




1 From the Weekly Epidemiological Record of the World Health 
Organization, March 7, 1986 issue. 
2 For simplicity, HIV has been substituted throughout this copy where 
LAV/HTLV-111 was originally used. They are equivalent terms. 
* A single negative test for HIV may be applied here if it is an 
antibody test by ELISA immunofluorescent, or Western blot methods, 
becuase such tests are very sensitive. Viral cultures are less 
sensitive but more specific, and so may be used only if positive 
but not if negative. If multiple antibody tests have inconsistent 
results the result applied to the case definition should be that of 
the majority. A positive culture, however would overrule negative 
antibody tests. 
** A postive test for HIV may consist of a reactive test for antibody 
to HIV or a positive culture (isolation of HIV from a culture of 
the patient’s peripheral blood lymphocytes). If multiple antibody 
tests have inconsistent results, the result applied to the case 
definition should be that of the majority done by the ELISA 
immunoflorescent or Western blot methods. A positive culture, 
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ACQUIRED IMMUNODEF^ 
ADULT CONFIDE^* 
(Patients ^13 years of = 
FORM APPROVED 
OMB NO. 0920-0009 
EPARTMENT of HEALTH AND HUMAN SERVICES acquired IMMUNODEFICIENCY SYNDROME (AIDS) 
STmVMSltlwfc'oNTROL ADULT CONFIDENTIAL CASE REPORT 
IDS PROGRAM, ClD, ATLANTA, GEORGIA 30333 (Patients >13 years of age at time of diagnosis) 
This report is authorized by law (Sections 304 and 306 of the Public Health Service Act. 42 USC 242b and 242k). Response m this case is voluntary tor federal 
ovtrnment purposes, but may be mandatory under state and local statutes Your cooperation is necessary for the understanding and control of AIDS Information m 
)i surveillance system that would permit identification of any individual or establishment is collected with a guarantee that it will be held m confidence will be used 
nly for the purposes stated m the assurance on the reverse of the form, and will not otherwise be disclosed or released without the consent of the individual or the 
stiblishment in accordance with Section 308(d) of the Public Health Service Act (42 USC 242m). 
I COMPLETED^ DATE FORM ( 
Mo. Day Yaar 
CD 
COC PATIENT NUMBER 
f HEALTH DEPARTMENT USE ONLY 
j^SOUNDEX^jt 
NAMECODI 
' £ - ft »* 
STATUS OF THIS 
wSl. REPOR' 
| 21 Update Report 
REPORTING HEALTH#*^-- 
DEPARTMENT 
stro^r.:: * ;_V—„,.... 1 Sk 
City? .:•>-* - • - 
County___- - 
STATE PATIENT NUMBER 
■* 
cr rY/i :ol INT Y Pi ATI ENT NL MBER 
I. BASIC PATIENT INFORMATION 
DATE OF BIRTH AGE AT DIAGNOSIS CURRENT STATUS DATE OF DEATH SEX 
MO. Day Year 
OF AIDS 
[71 Alive m Dead Mo. Day Year 
Y ears | [E Unknown 
□ 
RACE/ETHNICITY 
[71 White (not Hispanic) Black (not Hispanic) Hispanic 
0 Asian/Pacific Islander \T] p^nNaxwT'1 [1] Not Specified 
COUNTRY OF BIRTH 
Q] U.S. Q] Canada [7] 
1 5 | Mexico Other (specify)_ 
Dominican •c m •« 
Republic LfJ Ha',' 
RESIDENCE AT ONSET OF ILLNESS SUGGESTIVE OF AIDS: 
City_ County. 






. Country . 
II. SOCIAL AND RISK FACTORS 
AFTER 1977 AND PRECEDING THE DIAGNOSIS OF AIDS, DID THIS PATIENT: (check all that apply) 
• Have sexual relations with a male partner? . 
• Have sexual relations with a female partner?. 
• Use needles for self-injection of drugs not prescribed by a physician? 
• Receive any blood products (i.e.. factor VIII or IX. cryoprecipitate, 
or fibrinogen) for the treatment of a coagulation disorder?. 
Ye* No Unk 
□ mu] 
• If yes. 
specify disorder: 
[T*| Hemophilia A Q] Hemophilia B 0 Other, 
(factor VIII) (factor IX) specify:. 
• Have heterosexual relations with any of the following: (check all that apply) 
• I.V. drug abuser  
• Bisexual man  
• Person with hemophilia/coagulation disorder. 
• Blood transfusion recipient with AIDS or documented HIV infection — 
• Person with AIDS or documented HIV infection . 
• Person born in a country where heterosexual transmission predominates, 
(e.g., African or Caribbean country) Specify country:. 
• Has patient received a transfusion of blood/blood components?. 
Mo 
• If yes. and this is only risk factor. 
give date of first and last transfusion: First 
• Work in a health-care or clinical laboratory setting? 




m E E 
□ e E 
□ E E 
□ E E 
□ 0 E 
m E E 
□ E E 
m E E 
m E E 
□ E E 
□ E E 
y 

SYNDROME (AIDS) Physician's Name 
SE REPORT Hospital: _ 
Telephone No. 
Tie of diagnosis) Person Completing Form: 
Medical Record No. 
Telephone No.: (_1_ 




I jidiasis. bronchi, trachea, or lungs 




xtrapulmonary □ NA 
DISEASE DIAGNOSIS 
Definitive* Presumptive 
Kaposi's sarcoma □ m 
Lymphoma. Burkitt's (or equivalent term) m NA 
Lymphoma, immunoblastic (or equivalent term) NA 
itococcosis, extrapulmonary m NA Lymphoma, primary in brain m NA 
| itospondiosis, chronic intestinal m NA Mycobacterium avium complex or M. kansasii. r—i __. disseminated or extrapulmonary LlJ LEJ 
( rnegaiovirus disease (other than in liver, 
jleen, or nodes) m NA M. tuberculosis, disseminated or extrapulmonary 0 
I rnegaiovirus retinitis (with loss of vision) m 0 Mycobacterium, of other species or unidentified i—i species, disseminated or extrapulmonary LU 0 
I encephalopathy □ NA Pneumocystis carinu pneumonia E3 
I essimplex: chronic ulcer(s) (>1 mo. duration); 
i onchitis. pneumonitis, or esophagitis □ NA Progressive multifocal leukoencephalopathy □ 
jplasmosis, disseminated or extrapulmonary m NA Salmonella septicemia, recurrent m 





Wasting syndrome due to HIV □ NA 
'Refer to instructions on back for definition 
of definitive diagnosis. 
Of diseases checked above, 
date first disease diagnosed: 
Mo 
IV. LABORATORY DATA 
IV SERUM ANTIBODY TESTS: 




'ELISA ......... .m 0 0 0 
1 Western blot/immunofluorescence assay  .m 0 0 0 
Other (specify)  .m 0 0 0 
•Inc - Inconclusive 
IV DETECTION TESTS: 
Applicable only if serum antibody tests are not positive.) 









0 antigen test and reverse transcriptase detection  
.m 0 0 0 
'Other HIV test (specify) . .m 0 0 0 
•Inc » Inconclusive 
HIV tarts ware not positive or were not done, does this patient have an 




















CDC COMPOSITE CLASSIFICATION SYSTEM FOR HIV INFECTIONS 
Group I Acute Infection: HIV positive with an 
acute, mononucleosis-like symdrome. 
Group II Asymptomatic Infection: no history of 
any ARC symptoms. Subclassifications 
include lymphopehia, thrombocytopenia, 
and decreased numbers of T^ cells. 
Group III Persistent Generalized 
Lymphadenopathy: palpable 
lymphadenopathy (nodes > to 1 cm). 
Group IV Other HIV Disease: (each subgroup may 
include patients who are minimally 
symptomatic as well as patients who 
are severely ill.) 
Subgroup A Constitutional Disease: one or more 
of the following: fever > 1 month, 
weight loss > 10% of baseline, 
diarrhea > 1 month, and absence of 
concurrent illness other than HIV to 
explain findings. 
Subgroup B Neurologic Disease: one or more of 
the following: dementia, myelopathy, 
or peri feral neuropathy; and the 
absence of a concurrent illness or 
condition, other than HIV infection to 
explain the findings. 
Subgroup C Secondary Infectious Diseases: the 
diagnosis of an infectious disease 
associated with HIV infection or at 
least moderately indicative of a 
defect in cell-mediated immunity. 
C-l Any of the 12 OI’s that qualifies for 
the diagnosis of AIDS.(see appendix 
I). 
C-2 One of the 6 following diseases: oral 
hairy Leukoplakia, multidermal herpes 
zoster, recurrent salmonella 
bacteremia, nocardiosis, tuberculosis, 
or oral candidiasis. 
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Subgroup D Secondary Cancers: one of the 
following: K.S., non-Hodgkins 
lymphoma (small noncleaved lymphoma or 
immunoblastic sarcoma), or primary 
lymphoma of the brain.) 
Subgroup E Other Conditions in HIV Infection: 
chromic lymphoid interstitial 
pneumonitis, or signs and symptoms 
attributable to HIV infection or co- 
exisiting disease the course or 
management of which may be complicated 




SUMMARY OF SURVIVAL STUDIES IN AIDS 
(All survivals in Months and Tenths of Months) 
San Francisco'** U.K.43 N.Y.C. #143* N.Y.C. #24^ 
May’83 June’85 Jan.’84 Jan.’86 
n=165 n=168 n-1,410 n=5,833 
KS 21 21.2 29.2 25.0 
POP 9 12.5 8.2 10.6 
KS+PCP -- 6.6 14.2 12.7 
Other ** 9 13.3 4.2 7.2 
KS+Other -- -- 15.2 10.8 
PCP+Other _ _ - 10.3 10.0 
Notes: 
* Rivin et al.’s data was subsumed in Rothenberg et al. It is 
reported here because the earlier medians were different than 
Rothenberg et al.’s findings. 
** Other was defined as any 01 or neoplasm that qualified for the AIDS 
diagnosis excluding POP or KS. 

Form Complete: 
Clinic Chart _Other Records to Review 
_In~patient Record: _Records Not Available 







D.O.B.__ Age_ Race_ 







_Homosexual Male _IVDA _Blood Trans. 
__Haitian _Sexual Partner _N.K.R. 
Last known Exposure:_ 
notes: 
ZT DIAGNOSIS 
_P.C.P. _P.C.P. & R.F. _M.A.I. 
_K.S. _Other (_) 
NECROPSY 
#___ date_ 
(was the brain evaluated?) 
'ITERVALS 
Zero Time_ Date of Death 
Date Last Doc. Alive_ 
Source_ 
* to Admission_ *to ZT_ 
= to admission_ = to ZT_ 
Adm to ZT ZT to end 





_Cigarette Smoker _ppdx _yrs. 
_complications 







(close to ZT steroids?, antibx?, 
drugs known to alter C.B.C.'s? ) 
Pre-Zero Time Line 

;R0 STATE DATA 
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History ZT Exam 
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lymphadanopathytoiher poss. cauaaa 
alta 4 alt* 
parlod praaani 
• ■* Cramp* 
pain 
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Temp._ Resp. Rate_ 







ZT Paraclinical Data 
T Cell Studies: 
W 
date source 




_Mumps _Candida _PPD 
















Nutr. Consult? date_ 
Weight 
Reported Ave Wt_ Calc Ave Wt_ 
Adm Wt_ Calc Wt Loss 
Reported Wt Loss_ %Wt Loss _ 
Height_ Index B. Wt_ 
RaSi°fogy/*lbumln- 














est. prior to code 
_est. s/p code 
_pt unresponsive 
_pt responsive 
Discussed with patient 
Discussed with patient's family 
Patient died 




findings date source 
BIOPSIES 
tissue findings date/source 
RADIOLOGIC STUDIES 
study findings date source 




note pztr or a/pzt 
si«fiiaa 
klhir 
JC Vlrua (papava »|,uaj 
Natty ImhiflAl, 
■ucaculanaout 
".»" «»»'—» •^..naaphalapalhr 
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A.*.f»lllua fu.|ialua (| alh,f |pM|#iJ 
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Cf yplocoocva naaraiaana 
Cacctdlaldaa |M|l|a 
Ml ileplataa oapaulalua 
IfBa-raa.i, (aadarat .pool,,) 
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'"•wmkmUi eatlnll 
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•bactarlal. 
Non-tub*tcutIn Pyaabaclarla 
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®Jh,r ,f "at Imoanl, aoucea of dl*ato|n*tap 
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,MI-u xi5;.:. i,s\s 15 5L-» 
■omiodobln** lyaphoaa (hl,lolo,|a 8,apaf) 




FORM COMPLETED: Date: 









CODE AGE RACE SEX 
[ ] [ ] [ ] [ ] [ ] [ 1 [ ] 1 W C ] 1 M 
(1) (2) (3) (4) (5) (6) (7) 2 B (8) 2 F 
3 H 
4 0 
IVDA HOMOM HETERO BLOOD TRANS 
[ ] 0 NKR [ ] 0 NKR [ ] 0 NKR [ ] 0 NKR 
(9) 1 + (10) 1 + (ID 1 + (12) 1 + 
PCP MAI KS CRYPTO TOXO 
[ ] 0 None [ ] 0 None [ ] 0 None [ ] 0 None [ ] 0 None 
(13) 1 + (14) 1 + (15) 1 + (16) 1 + (17) 1 + 
BRAIN CA CANDIDA ESOPHAGITIS OTHER 
[ ] 0 None [ ] 0 None [ ] o None 
(18) 1 + (19) 1 + (20) 1 + 
* - ZT WT LOSS RPT LOSS/PERIOD 
[ ] [ ] •[ ] mo [ ] 1 None [ ] [ ] lbs in [ ] [ ] .[ ] mo 
(21) (22) (23) (24) 2 + (25) (26) (27) (28) (29) 
_F/C/NS_ 
[ ] 0 None 
(30) 1 Fever 
2 Chills 
4 Night Sweats 
HIGHEST F 
[][][] F 
(31) (32) (33) 
PERIOD OF S. Sx's 
[ ] [ ] •[ ] 
(34) (35) (36) 
jN & SKIN: LN SKIN LESIONS EXTENT 
[ ] 0 None [ ] 0 None [ ] 0 None 
(37) 1 + (38) 1 KS-like 
2 Herpetic 
4 Rash 
(39) 1 One Loc, £10 Lesions 
2 Two Loc, or >10 Les 
3 > Three Loc 
»I: 
(Sig Diarrhea= 
Constant * £1 mo) 
Hx OF THRUSH 
[ ] 0 None 
(40) 1 + 
FREQ DIARRHEA PERIOD OF D 
[ ] 0 None [ ] [ ] .[ ] mo 
(41) 1 Intermit (42) (43) (44) 
2 Constant 
CLASS OF D 
[ ] 1 not sig 





[ ] 0 None 




[ ] 0 None 
(47) 1 DOE 
2 At Rest 
PERIOD OF P Sx's 
[ ] [ ] •[ ] 
(48) (49) (50) 
EYE 
[ ] 0 None 





[ ] [ ] 0 None 







[ ] [ ] 0 None 











T PARACLINICAL DATA 
MMUNOLOGICAL DATA: 
Hx of REL DZ 
[ ] [ ] 0 None 
(56) (57) 1 Hep B 
2 CMV 
_SEROLOGIES_ 
[ ] [ ] 0 None 





[ ] 0 None, Social 
(60) 1 Noted 
2 Evidence sd 
eff (Note) 4 Syph 
8 Gono 
16 Endocarditis 
CIG SMOKING (Note) 
[ ] 0 None 
(61) 1 <1 ppd * 10 yrs 
2 >1 ppd * 10 yrs 
_PSYCH Hx_ 
[ ] [ ] 0 None 
(62) (63) 1 Rel to Homosex 




[ ] 1 Inpt (Yale) 
(64) 2 Outpt 
4 Delayed ZT 
_TEMP_ 
[][][] F 
(65) (66) (67) 
R.R. 
[ ] [ ] 
(68) (69) 
THRUSH 
[ ] 0 None 
(70) 1 + 
_LN_ 
[ ] 0 None 
(71) 1 Detectable 
2 Pronounced 
_KS_ 
[ ] 0 None 
(72) 1< 10 Lesions 
One Loc 
2 >10 Lesions 
Two Loc 
3 > Two Loc 
_EYE_ 
[ ] [ ] 0 None 
(73) (74) 1 Retinal Abn 
2 Other 
ENCEPHALOMENIGEAL SIGNS 
[ ] [ ] 0 None 
(75) (76) 1 Stiff Neck 
2 Seizures 
4 Severe Lethargy 
8 Photophobia 
OTHER NEUROLOGIC SIGNS 
[ ] [ ] 0 None 






[ ] 0 None 
(79) 1 Papill Edema 
2 Pupil Dilation 
GROUP 
[ ] 1 Devel 
(80) 2 Chall 
_CODE #_ 
[ ] [ ] [ ] t 1 
(1) (2) (3) (4) 
ANERGY_ 
[ ] 0 Not Tested 
(5) 1 Norm 
2 Partial 
3 Complete 
_REL TO ZT 
[ ] +0 [ ] [ ] 





[ ] [ 3% 
(10) (11) 
T /pi 
[3 [3 [ 3 







[ 3 [ 3 [3 
(17) (18) (19) 
T /T 
4 8 _REL TO ZT_ TECH LAB 
[].[][] [ 3 +0 [ 3 [ 3 • [ 3 mo [ ] 1 Yale 





S B L M E 
;BC: /////// 
laic Lymp=WBC_* %L_=_ 
HCT 
[ ] []-.[] 
(28) (29) (30) 
WBG 
[ ] .[ ] 
(31) (32) 
PLTS ADEO? 
[ ] 0 Not Measured 




[ ] [ ] [ ] [ ] 
(33) (34) (35) (36) 
PLTS 
[ ] [ ] [ ] K 
(38) (39) (40) 
BMF 
[—] Revised 
(41) 1 Single Line Fail 
2 Two Lines Fail 
3 3 Lines Fail 
SEP RATE 
[ ] [ ] [ ] 
(42) (43) (44) 
LAB 
[ ] 0 ? 
(45) 1 Yale 
2 Other 
ESPIRATORY DATA: 
m Air ABG/CXR 
EUROLOGIC DATA: 
T LOSS DATA: 
PRO/ALB: 
T: - 1BW: 
VE WT: 
DM WT: - CALC WT LOSS 
r1L 
[ ] [ ] [ ] 
(46) (47) (48) 
PCO' PO- CXR 
[ ] [ ] 
(49) (50) 
[ ] [ ] [ ] 
(51) (52) (53) 











[ ] [ ] 0 None 
(56) (57) 1 Wnl 
2 Ring Enhancing Lesion 
4 Mass Effect 
8 Other 
ALB 
[ ] .[ ] 
(58) (59) 
NL STATE ADM STATE 
[ ] 0+ 
(60) 1- 
[ ] [ ] 
(61) (62) 
[ ] 0+ [ ] [ ] 
(63) 1- (64) (65) 
% CALC WT LOSS 









[ ] [ ] / [ ] [ ] / [ ] [ ] 
(68) (69) (70) (71) (72) (73) 
ALIVE/DEAD 
[ ] 0? 
(74) 1 Alive 
2 Dead 
ZT - END 
[ ] [ ] •[ ] 
(75) (76) (77) 
AUTOPSY 
[ ] 0 None 
(78) 1 + 
SURPRISES ? 
[ ] 0 None 
(79) 1 + 




[ ] 0 None 





MANUAL FOR COMPLETION OF EXTRACTION/DATA ENTRY FORM 
ORIENTATION: 
The form has a space at the top for bookkeeping, a space on the 
left hand margin for longhand notes, and a coding area on the right 
for data entry. The numbers underneath spaces on the data-entry 
portion correspond to columns in a computer format, the numbers go 
from 1-80 and then repeat. 
DEFINITIONS: 
Throughout this manual certain definitions apply: 
Zero time (ZT1: This is the time with which all intervals are 
measured, including survival. Zero time is either the day upon which 
the patient was diagnosed as having AIDS by CDC criteria (see Appendix 
I), or an YNHH admission to medicine or neurology or a visit to the 
AIDS clinic at YNHH following the actual date of diagnosis. For a 
more specific explanation see "determining Zero Time" below and 
Appendix VII. 
Interval (*-): An interval is the time elapsed between two 
date points (one of which is always zero time). It is recorded in 30- 
day months and tenths of months (.1 month equals 3 days, 2 days are 
rounded up to .1, 1 day is rounded down to 0.) For example, if a 
patient had ZT 6/23/83 and died on 9/30/83, the patient’s survival 
interval would be recorded as 3.2 months. 
Recent: any history or physical examination recorded within one 
month of ZT. 
Sufficient data for an extraction: There must be a recent 
history and physical exam that are reasonably complete and at least a 
complete blood count. 
Additive: Certain variables such as F/C/NS are noted as 
"additive". This simply means that a given patient may have more than 
one of the symptoms or signs listed. Simply add up the score and 
enter the total. A patient with fevers and chills would have a score 
of 3, a patient with chills and night sweats would have a score of 6, 




The top section of the form is used to keep track of the 
progress of the extraction. It includes the date the extraction 
began, and the number of inpatient volumes that exist and that have 
been reviewed. Note the existence of and reviewed status of an 
outpatient file (designated by a yellow sticker on its outside). A 
separate index card is kept for each patient’s identification number 
and name. This card can be used to note any problems in completing 
the extraction and the final outcome (i.e. "extraction complete" or 
"lost to follow up" or "volume V never found therefore extraction done 
after original diagnosis" etc.) 
DETERMINATION OF ZERO TIME (ZT): 
Locating the "zero time admission" involves several steps (see 
Figure 2). First, using the WHO/CDC criteria in Appendix I, determine 
the time at which the patient first meets the criteria for the AIDS 
diagnosis. If this diagnosis was made at YNHH, either as an inpatient 
or as an outpatient, and if there are sufficient records for an 
extraction, then ZT is the date on which the CDC criteria were 
satisfied. If the data are insufficient, or if the patient was 
originally diagnosed at an outside hospital, then ZT is the date of 
the first recorded visit after diagnosis to the YNHH AIDS Clinic or 
admission to YNHH, for which sufficient data are available for an 
extraction. 
Note that all information available up to the designated zero 
time can be used in extraction of the ZT history, ZT physical exam, 
and ZT paraclinical data. Any data that becomes available after ZT is 
not eligible for classifying patients at ZT, but pertinent post-ZT 
events and findings should be noted within the left margin if they 
shed light on the patient’s eventual outcome. 
Patient’s height, AZT therapy, DNR status, T cell studies, 
Anergy Panel and Autopsy data should be coded whether or not it 
occured at ZT. Be sure to note the interval between the time of the 
anergy panel, the T cell studies, and the AZT therapy and ZT. This 
data will have to be analyzed separately since it was not collected 
prior to or on ZT. 
IDENTIFICATION AND DEMOGRAPHIC DATA (1-81: 
1-4. ID Code: write the patient’s full 7 digit hospita unit 
number in left margin of the form. Enter last four 
digits on code sheet in these columns. 
5-6. Age: calculated from birth date on ER sheet or ID card. 
Cite as age on last birthday before ZT. 
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7. Race: the consensus of the emergency room sheet and 
what is reported on the history and physical exams. 
8. Sex: as reported in physical exam. 
ZT HISTORY: 
Any history, physical exam or paraclinical tests performed prior 
to ZT are available data for ZT history. Also any history recorded on 
ZT is available. If a specific symptom is occassionally mentioned, 
but not uniformly, and is not specifically denied in any history, 
assume it is present. If histories have conflicting accounts of 
specific symptoms, time periods, etc, give most weight to the medical 
student’s history and to those histories that seem most complete. If 
there seems to be a great deal of controversy take a consensus account 
and note the controversy in the left margin. 
RISK (9-12): 
for each category of risk code 0 for No Known Risk (NKR), 1 for 
a positive history. 
9. IVDA: any record of intravenous drug abuse. 
10. HOMOM: any record of male homosexual intercourse. 
11. HETERO: heterosexual partner of an individual known to 
be at high risk (i.e. to be an IVDA, Homom, Blood Trans) 
or known to be HIV positive. 
12. BLOOD TRANS: any hemophiliac or anyone else receiving 
large amounts of blood or blood products within the last 
10 years.(Note within left margin nature of transfusions 
and when they were recieved.) 
ZT DIAGNOSTIC COMPONENT (13-20): 
13. PCP: Pneumocystis carinii identified via gram stain or 
silver stain of sputum, bronchial washings, or bronchial 
biopsy. 
14. MAI: Cultures from blood, urine, sputum, or surgical 
specimens positive for any strain of atypical 
mycobacterium (and not considered merely a contaminate). 
15. KS: Skin punch biopsy proven Kaposi’s Sarcoma. 
16. Crypto: Crvptococcus identified in either cerebral 
spinal fluid via a positive india ink test or a positive 
antigen titer, or Crvptococcus cultured or identified on 
smear of blood. 
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17. Toxo: ToxodIasmosis identified in brain bioDsv SDecimen 
or in organs other than liver, spleen, or lymph nodes. 
18. Brain Ca: Brain biopsy proven lymphoma or progressive 
multifocal leukoencephalopathy (PML). 
19. Candida EsoDhaaitis: EndoscoDic bioDsv Dositive for 
fungal elements. 
20. Other: (see WHO paper in Appendix I) Any other 
opportunistic infection that qualifies for the diagnosis 
of AIDS. 
21-23. *-ZT: Interval from first symptoms attributable to AIDS 
or ARC, to ZT. 
SYSTEMIC SYMPTOMS (24-36): 
24. Wt Loss: l-(None) if patient reports no weight loss; 2- 
(present) if he/she reports any. 
25-26. Rpt Loss: Record number of pounds reported lost. 
27-29. Period: Interval over which weight was lost. 
30. F/C/NS: (additive) Fever, chills, and/or night sweats. 
Positive if symptoms reported in any history within the 
*-ZT interval. 
31-33. Highest F: Highest fever by patient’s report or 
previous physical exam or admission fever if it is 
highest. 
34-36. Period of S.Sx’s: Period over which systemic symptoms 
(fever/chills/night sweats) have been present. 
LN & SKIN (37-39): 
37. LN: Positive if lymph nodes are enlarged by patient’s 
account or on physical examination prior to ZT. 
38. Skin Lesions: (additive) KS-like lesions positive if 
patient reports purplish maculo-papular lesions, 
Herpetic positive if clustered vesicular lesions 
reported, and Rash positive if purpuric lesions present. 
39. Extent: if KS-like lesions present record only extent 
of KS: if no KS. but Heroetic lesions record only for 
Herpetic lesions; if only rash present, record for rash. 
One location equals one arm, one leg, or one quadrant of 




40. Oral Thrush: positive if present by previous exam or if 
patient reports dysphagia or actually seeing white 
plaques on the inside of his/her mouth. 
41. Freq Diarrhea: \ if diarrhea described as occasional or 
intermittent; 2 if described as loose, watery or 
requiring persistent use of opioids (e.g. Lomotil). 
42-44. Period of Diarrhea: Interval over which diarrhea has 
been a problem. 
45. Class of Diarrhea: If #41 = 2 and #42 through 44 > one 
month than class is "significant" (#45 = 2). If data 
missing or period of severity less, than #45 = 1. 
PULMONARY (46-50): 
46. Cough/CP: (additive) +1 if cough reported; ±2 if non- 
pleuritic chest pain reported; +4 if pleuritic chest 
pain reported. 
47. Dyspnea: 1 if short of breath on exertion, 2 if short 
of breath at rest. 
48-50. Period of P Sx’s: interval of longest pulmonary symptoms 
presence. 
NEUROLOGIC SYMPTOMS (51-55): 
51. Eye: (additive) +1 if white spots seen on funduscopic 
exam; +2 if patient reports visual blurring. 
52-53. Encephalomenigeal: (additive) +1 if patient complains 
of neck stiffness; +2 if patient has developed new onset 
seizures in past 6 months; ±4 if patient or patient’s 
family reports new severe lethargy or confusion; ±8 if 
patient complains of photophobia. 
54-55. Neurologic Deficits: (additive) +1 if patient has newly 
developed difficulty with speaking; +2 if patient 
complains of complete or partial paralysis of any 
extremity; ±4 if patient or family complains of 
inappropriate behavior or extreme disorientation, or if 
history taking is made extremely difficult secondary to 
patients compromised mentation; +8 if other noteworthy 




56-57. Hx of Rel Dz: (additive) +1 if history of hepatitis B 
infection; +2 if history of cytomegalovirus (CMV) 
infection; +4 if history of syphilis; +8 if history of 
gonorrhea; +16 if patient had multiple positive blood 
cultures without a clear alternative source (such as an 
infected central line). Be sure to note all evidence 
for and against endocarditis and record date of blood 
cultures as well as organisms grown. 
58-59. Serologies: (additive) +1 if positive titer for 
Hepatitis B; +2 if positive titer for CMV; +4 if 
positive for ToxodIasmosis: +8 if positive titer for 
Cryptococcus. 
60. ETOH Abuse: 1 if abuse noted in chart at any time; 2 if 
evidence of side effects (PE, liver biopsy positive for 
fatty liver or cirrhosis, evidence of cerebellar 
compromise, etc.) 
61. Cig Smoking: \ if less than or equal to 10 pack years, 
or if patient stopped smoking over 2 years ago; 2 if 
greater than 10 pack year history. 
62-63. Psych History: (additive) +1 if related to 
homosexuality (i.e. if patient sought psychiatric 
counselling for problems associated with homosexuality); 
+2 patient was placed in drug rehabilitation program; +4 
if patient was considered psychotic; +8 if patient was 
considered suicidally depressed or had actually 
attempted suicide. 
ZT EXAM (64-801: 
Any physical exam sign described within one month of ZT is 
recordable. If there are conflicting reports of a particular finding 
give most weight to house officer with the most seniority and 
expertise in the area of the finding. For example, a pulmonary fellow 
would give the most authoritative account of the lung exam, etc. 
64. ZT: I if ZT is as inpatient at YNHH; 2 if ZT is as 
outpatient at YNHH; 4 if ZT is not at time of original 
CDC AIDS dx. 
65-67. Temp: If ZT is within 2 days of admission use ER temp. 
If no ER temp, use highest PE temperature. 
68-69. RR: record highest respiratory rate given. If range 
given (i.e. 30-40) pick mean of range (i.e. 35). 
70. Thrush: I if present. 
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71. LN: 1 if lymph nodes detectable; 2 if >3cm. or 
"pronounced". 
72. KS: record if house officer believes lesions suspicious 
for KS, locations determined in same manner as #39. 
73-74. Eye: (additive) +1 if abnormality seen on fundoscopic 
exam; +2 if other abnormalities of eye(s) observed 
(periorbital swelling, conjunctivitis, etc.) 
75-76. Encephalomenigeal Signs: (additive) +1 if stiff neck 
or painful to touch chin to chest; +2 if seizure 
witnessed; +4 if patient is difficult to keep awake 
during examination or described as lethargic, obtunded, 
or stuporous; +8 if patient unable to tolerate bright 
light during exam. 
77-78. Other Neurologic Signs: (additive) +1 if patient has 
difficulty speaking during exam;+2 if patient 
demonstrates significant lower extremity weakness or 
paralysis; +4 if patient not oriented to person, place, 
and/or time; +8 if other neurologic deficits (i.e. 
abnormalities in neuro exam) are present. 
79. Mass Effect: (additive) ±1 if papilledema present; +2 
if one or both pupils dialated (without benefit of 
sympathomimetics). 
80. Group: if patient placed on AIDS Clinic list up to and 
including July 24, 1986 code as 1; if patient added 
after, code as 2. 
ZT PARACLINICAL DATA(l-65): 
1-4. Same ID code as 1-4 under identification. 
5. Anergy: \ (normal) if PPD negative and all controls 
positive; 2 (partial) if PPD negative and at least one 
but not all controls positive; 3 (complete) if all tests 
negative. 
Anergy Rel to ZT (6-9): 
6. 0 if anergy tested after ZT; I if anergy tested before 
or on ZT. 
7-9. Interval: record period between panel and ZT. 
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T Cell Panel (10-27): 
preference given to panel closest to ZT. 
10-11. T4 percent 
12-14. T4 per micro!iter 
15-16. T8 percent 
17-19. T8 per micro!iter 
20-22. T4/T8 ratio 
T Cell Rel to ZT (23-27): 
23. 0 if tested after ZT; \ if tested before or on ZT. 
24-26. Interval between ZT and T Cell test. 
27. I if tested at YNHH; 2 if tested elsewhere. 
Complete Blood Count(28-45): 
Manual differential to be noted in left margin. Use CBC closest 
to ZT prior to any blood transfusions. If patient is receiving marrow 
suppressing medications such as trimethoprim sulfamethoxazol (i.e. 
Bactrim), amphotericin, pentamidine, etc. compare current CBC with one 
prior to treatment and if CBC is lower after treatment than use old 
CBC, if not use current CBC. 
28-30. Hematocrit record directly. 
31-32. White Blood Count/1000. If greater than 9.9 record as 
9.9 and note actual count on the side. 
33-36. Calculated Lymphocytes = (WBC) x (percent lymohicytes) x 
10 
37. Platelets: if listed only as "ADEQ" or "DECREASED" or 
"INCREASED" so record. If actual count given: < 140,000 
= decreased; > 400,000 = increased; all others are 
adequate. 
38-40. Platelet Count: record actual count if given 
41. Bone Marrow Failure (this category revised, ignore.) 
42-44. Sedimentation Rate record directly. 




46-53. Room Air Arteriolar Blood Gas: Use the room air ABG 
54-55. 
with the lowest p02 value prior to ZT. 
Chest X-Ray: (additive) +0 if not ordered or misplaced; 
+1 if read as "normal chest" or "no acute change"; +2 if 
"diffuse infiltrate," "multinodular interstitial 
pattern," or "cannot rule out P.C.P."; +4 if specific 
lobular infiltrate identified; ±8 if cavitary lesion" is 
specified. 
56-57. Head CT: (additive) ±0 if not obtained or misplaced; +1 
if read as "within normal limits"; ±2 if contrast and 
non-contrast studies are done and ring enhancing lesions 
are identified; +4 if "mass effect" noted; +8 if 
anything else of significance is noted (specify on 
left). 
Nutritional Data(58-67): 
This section cannot be completed without documentation of the 
patient’s height. Use the weignt/height chart (Appendix VII) to 
determine ideal body weight for patient. 
58-59. Albumin: record directly, value closest to ZT. 
60-62. Normal Weight State: Subtract ideal weight from weight 
reported as patient’s normal or usual weight. 
60. If result of calculation is positive, code 0 if negative 
code 1. 
61-62. Record number of pounds of difference. If no 
difference, code 0. 
63-65. Admission Weight State: subtract ideal weight from 
63. 
weight recorded on or near admission or ZT (give 
priority to weight closest to ZT). 
If difference of above is positive,0; if negative code 
1. 
64-65. Record number of pounds of difference; if no difference, 
code 0. 
66-67. % Calculated Weight Loss: subtract admission weight 
from normal weight and divide the difference by normal 
state. Record as %. If no weight loss or if weight 




68-73. Record the date of ZT by month/date/year. 
74. ? equals lost to follow up. Look at last date at which 
patient is known to be alive or dead and so record. 
75-77. Subtract ZT date from date of death and record 
difference in months and tenths of months. If patient 
alive or, if state unknown leave these spaces blank. 
AUTOPSY (78-79): 
Find final report of autopsy if done. Record autopsy number and 
major diagnoses. If any major diagnoses were unsuspected when patient 
was still alive code 1 in column 79. 
78. 0 if no autopsy done or report not found; \ if report 
found. 
79. Surprises: (see above and so note). 
AZT DURATION (80): 
Look at outpatient chart and summary list of AZT therapy from 
AIDS office and so record. If no AZT administered code as 0. If AZT 
given at any time, code as 1. Note date therapy started. 
DNR (Do Not Resuscitate) STATUS: 
Determine date of DNR status (if established) and note who was 
consulted as well as any specifics of the order. 

APPENDIX VII 





5’3" 125 129 
5’6" 135 140 
5’9" 149 153 
6’0" 161 166 
6’3" 176 181 
4’ 10" 97 102 
5’ 1" 106 109 
5’4" 114 118 
5’7" 123 127 
5 ’ 10" 134 138 
Notes: 
1 Taken from The Pacific Mutual 
Tables (updated 1986). 
Ape 
40-49 50-59 60-' 
Men 
130 131 . 130 
142 143 142 
155 156 155 
167 168 167 
183 184 180 
Women 
106 109 111 
114 118 120 
122 127 129 
132 137 140 
142 146 147 
Life Insurance Company 
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Eligible (117 pts.) 
1. Sufficient data = Reasonably complete history and physical exam with a complete 
blood count done within 1 month of zero time. The complete blood count must not be 
suspected of being depressed secondary to ongoing therapy with known 
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